

# CHAPTER 19

## POISONING

### POISONS INFORMATION CENTRES

<b>Poisons Information Helpline</b> (national service)		
<b>Red Cross War Memorial Children's Hospital Poisons Information Centre</b> Email: <a href="mailto:poisonsinformation@uct.ac.za">poisonsinformation@uct.ac.za</a> <a href="http://www.paediatrics.uct.ac.za/poisons-information-centre">http://www.paediatrics.uct.ac.za/poisons-information-centre</a>	24/7	0861 555 777
<b>Tygerberg Poisons Information Centre</b> Email: <a href="mailto:toxicology@sun.ac.za">toxicology@sun.ac.za</a> <a href="http://www.sun.ac.za/poisoncentre">www.sun.ac.za/poisoncentre</a>		
<b>University of the Free State Poison Control and Medicine Information Centre</b>	24/7	082 491 0160
Telephone numbers tested April 2022		

Access poisons information at: <https://www.afritox.co.za/>

The Afritox database is available free of charge to public hospitals in South Africa. If the above centres cannot be contacted, enquire at the nearest trauma and emergency unit.

### ENVENOMATION

Envenomation is an instance of poisoning by venom resulting from a bite or sting from an animal such as a snake, spider, scorpion, insect, or marine life.

<b>South African Vaccine Producers (SAVP):</b> For procurement of Snake/spider/scorpion antivenom: Email: <a href="mailto:benita.mouton@nhls.ac.za">benita.mouton@nhls.ac.za</a>	Office hours: (011) 386 6062/6063/6078 After hours 071 680 9897
--	--

### 19.1 INSECT BITES AND STINGS

T63.4 + (X23.99/X24.99/X25.99/X29.99)

#### DESCRIPTION

Toxicity due to insect bites and stings usually results in local effects only and systemic effects are rare. Occasionally, hypersensitivity reactions are encountered, varying from minor local inflammation to acute anaphylaxis. Multiple bee stings can result in systemic toxicity and may require ICU care.

## GENERAL MEASURES

- » Allergic reactions may be acutely life threatening.
- » Patients with multiple stings may develop delayed systemic toxicity. Beware of premature discharge from the healthcare facility.

## MEDICINE TREATMENT

Anaphylaxis: See section 20.7: Anaphylaxis/Anaphylactic Shock.

For pain:

- Paracetamol, oral, 500mg -1 g 4–6 hourly when required (to a maximum of 4 g in 24 hours)
  - Maximum dose: 15 mg/kg/dose.

LoE:IVb
---------

## 19.2 SNAKE BITES

T63.0 + (X20.99/W59.99)

### DESCRIPTION

In the majority of snakebite incidents, the offending snake is not identified. The table below illustrates the three main envenomation syndromes seen in South Africa: cytotoxic, neurotoxic and haemotoxic.

	Envenomation syndromes			
	Cytotoxic	Neurotoxic	Mixed cytotoxic & neurotoxic	Haemotoxic
Snake species	Puff adder, Gaboon adder, spitting cobras (Mozambique, black-necked, zebra), stiletto snake, night adders, horned adders	Black and green mamba, non-spitting cobras (Cape, forest, snouted)	Rinkhals, Berg adder, Peringuey's adder, desert mountain adder, garter snakes, shield-nose snake, coral snake	Boomslang, vine snakes
Clinical features of envenomation	Pain, swelling, bruising, blisters, necrosis, regional lymphadenopathy, hypotension, coagulopathy, compartment syndrome	Pins and needles, metallic taste, visual disturbances, ptosis, drowsiness, sweating, drooling, dysphagia, progressive weakness,	Combined cytotoxic and neurotoxic features	Spontaneous bleeding (can present late >24 hours after bite), headaches, dizziness, fainting

		respiratory paralysis		
Antivenom (when indicated)	Polyvalent antivenom for Puff adder, Gaboon adder, and Mozambique spitting cobra only	Polyvalent antivenom for all species	Polyvalent antivenom for rinkhals only	Boomslang monovalent antivenom for boomslang bites only

**Table 19.1:** Presentation and management of envenomation syndromes

To find pictures for the identification of snakes:

<http://www.cmej.org.za/index.php/cmej/article/view/2546/2581>

## GENERAL MEASURES

- » Most snakebites will not result in death.
- » Monitor all cases of snakebite for 24 hours.
- » Supportive and symptomatic management with/without antivenom is required.
- » Mechanical ventilation may be needed in some cases of neurotoxic envenomation.
- » Cases of haemotoxic envenomation may require fluid resuscitation including blood products.
- » True compartment syndrome is extremely rare in cytotoxic snakebites, as swelling is localised to the subcutaneous tissues. Fasciotomy is seldom indicated.

## MEDICINE TREATMENT

### Cleanse wound:

- Chlorhexidine 0.05% in water.

### Antibiotics: T79.3 + (X20.99/W59.99)

Antibiotics are seldom indicated unless there is evidence of secondary infection.

- Amoxicillin/clavulanic acid, oral, 875/125 mg 12 hourly for 5 days.

LoE:IVb

### Immunisation, primary or booster: (Z23.5)

- Tetanus toxoid vaccine, IM, 0.5 mL immediately, if not previously immunised within the last 5 years.

### In unimmunised or partially immunised patients:

- Tetanus immunoglobulin, human, IM, 250 units immediately.

**Analgesia**For mild pain:

- Paracetamol, oral, 500mg -1 g 4–6 hourly when required (to a maximum of 4 g in 24 hours)
  - Maximum dose: 15 mg/kg/dose.

For severe pain:**ADD**

- Morphine, IV, to a total maximum dose of 10 mg (See Appendix II, for individual dosing and monitoring for response and toxicity). LoE:IVb

**CAUTION**

Opioids increase the risk of respiratory depression particularly for neurotoxic envenomation, and if required, should only be used with caution in severe uncontrolled pain.

**Note:** NSAIDS are not recommended as they increase the risk of bleeding and renal failure, especially in patients with severe cytotoxic bites.

LoE:IVb<sup>ii</sup>**19.2.1 CYTOTOXIC AND NEUROTOXIC SNAKEBITE**

T63.0 + (X20.99/W59.99)

**MEDICINE TREATMENT****Polyvalent antivenom**

Used in some cytotoxic and neurotoxic envenomations, only where indicated (see indications below).

Available from South African Vaccine Producers (refer to the table above for contact details). See package insert for full details.

**Note:**LoE:IVb<sup>iii</sup>

- » In most cases, patients do not need and should not be given antivenom.
- » Adverse reactions to antivenom such as allergic reactions (10-30%) are common and may be severe. Pre-medication with adrenaline (epinephrine) may reduce the risk of severe adverse reactions to polyvalent snake antivenom.
- » The dose of antivenom is the same for adults and children.
- » Monitor for any deterioration in respiratory function as patients may need ventilation whether or not polyvalent antivenom has been given.
- » Antivenom should be given as soon as possible, however, administration may be considered even as late as 48-72 hours after the bite if there is continued clinical deterioration that indicates ongoing venom activity.

LoE:IVb<sup>v</sup>Indications for polyvalent antivenom:

- » Signs of neurotoxicity.
- » Positively identified puff adder, Gaboon adder, Mozambique spitting cobra or rinkhals bites AND evidence of progressive severe cytotoxicity.

- » Unidentified snakebite AND evidence of progressive severe cytotoxicity.
- » Severe local cytotoxicity is defined as:
  - Swelling of the whole hand or foot within 1 hour
  - Swelling to the knee or elbow in less than 6 hours (or two joints above the bite site in 6 hours)
  - Swelling of the whole limb in less than 12 hours
  - Swelling progression > 5 cm/hour
  - Discolouration of the skin / necrosis at the bite site
  - A threatened airway due to swelling
  - Evidence of complications e.g. pseudo- or true compartment syndrome
  - Additional features of severe systemic cytotoxicity include:
    - Haematological abnormalities: Hb <8 g/dL, thrombocytopaenia, (<100 x 10<sup>9</sup>/L), raised INR or abnormal thromboelastography (if available)
    - Arrhythmias (rare). LoE:IIIb<sup>v</sup>
    - Shock

**Note:** Polyvalent antivenom is ineffective against the venom of: night adders, berg adders and other smaller adders, boomslang, and vine/twig snakes.

#### CAUTION

Never administer antivenom without being prepared to manage acute anaphylaxis.

#### Administration and polyvalent antivenom dose:

- Pre-treat with adrenaline (epinephrine), SC, 0.25 mL of 1:1000 solution.

**Note:** This is contraindicated in patients with IHD, stroke, uncontrolled hypertension, and tachyarrhythmia. LoE:IIa<sup>vi</sup>

- Polyvalent snake antivenom, slow IV infusion.
  - This guidance refers to the antivenom produced by South African Vaccine Producers. For any other product refer to the relevant package insert for guidance. LoE:IVb<sup>vii</sup>
  - 1 ampoule contains 10 mL antivenom.
  - Cytotoxic snakebite (unidentified snake): give 50 mL,
  - For puff adder bites: the initial dose is 80 mL.
  - For Mozambique spitting cobras the initial dose is 100 mL
  - Neurotoxic snakebite: give 80–100 mL (and up to 200 mL in black mamba bites).
  - Dilute in sodium chloride, 0.9%, 200mL; for example, LoE:IVb<sup>viii</sup> if 8 ampoules are required, remove 80 mL from 200 mL saline bag and replace with 80 mL antivenom.
  - Administer IV, over 30 minutes.
  - Reassess once the infusion is completed. A repeat dose may be given if there is ongoing neurotoxicity or cytotoxicity.

## 19.2.2 BOOMSLANG SNAKEBITE

T63.0 + (X20.99/W59.99)

### DESCRIPTION

Boomslang venom is haemotoxic. A consumptive coagulopathy with hypofibrinogenaemia and bleeding usually sets in within 6–36 hours after the bite.

### GENERAL MEASURES

- » In suspected boomslang bite, a whole blood clotting time is a useful bedside test, especially in rural areas. Place 5 mL of blood in a dry glass test tube and leave at room temperature for 20 minutes. Normal clotting time varies from 5–20 minutes. It is important to repeat these over a few days.
- » Other investigations include FBC, activated PTT, prothrombin time (INR), fibrinogen, D-dimer, and monomers.

**Note:** Polyvalent antivenom is not effective in boomslang bites.

### Boomslang monovalent antivenom

Indicated for all boomslang bites with evidence of haemotoxicity.

Available from South African Vaccine Producers (refer to the table above for contact details). See full details in the package insert.

#### CAUTION

Never administer antivenom without being fully prepared to manage acute anaphylaxis.

- Boomslang monovalent antivenom, slow IV infusion, 20 mL diluted in 50–100 mL sodium chloride, 0.9% or dextrose 5%, administered over 5–10 minutes.
  - The dose of antivenom is the same for adults and children. LoE:IVb<sup>ix</sup>
  - Spontaneous systemic bleeding should stop within 15–30 minutes and blood coagulability be restored within 6 hours of administering antivenom.
  - Re-evaluate regularly: Consider a repeat dose of 10 ml of antivenom if there is ongoing evidence of coagulopathy after 6 hours.

## 19.2.3 SNAKE VENOM IN THE EYE

S05.9 + (X20.99/W59.99)

### DESCRIPTION

Snake venom in the eye, particularly from various species of spitting cobras and rinkhals, can cause local cytotoxic effects. Clinical presentation ranges

from periocular swelling and mild conjunctival and corneal inflammation, to frank corneal ulceration and perforation with eventual blindness.

## MEDICINE TREATMENT

### Instil local anaesthetic:

- Local anaesthetic ophthalmic drops, e.g.:
- Tetracaine 1%, drops (if available), instil 1 drop into the affected eye(s) before irrigation. LoE:IIIb<sup>x</sup>
  - Irrigate the eye thoroughly for 15–20 minutes with water or sodium chloride, 0.9% to dilute or remove the toxin.

### Topical antibiotics:

- Chloramphenicol 1%, ophthalmic ointment 8 hourly for 7 days.
  - Apply chloramphenicol eye ointment and cover the affected eye with an eye patch. LoE:IVb

**Note:** Do not instil polyvalent antivenom in the eye or give systemically.

LoE:IVb<sup>x</sup>

## REFERRAL

Refer all patients to an ophthalmologist.

## 19.3 SCORPION ENVENOMATION

T63.2 + (X22.99/W59.99)

### DESCRIPTION

Medically important scorpions in Southern Africa are of the genus *Parabuthus* (*P. granulatus* and *P. transvaalicus*). These are large scorpions measuring 7–15 cm in length. Features useful in their identification are a relatively large tail and small pincers, so-called thick-tailed scorpions. Scorpions from the Scorpionidae family (e.g. *Hadogenes*, *Opisthophthalmus*) are thin-tailed with large pincers.

To view pictures for the identification of scorpions:

<http://www.cmej.org.za/index.php/cmej/article/view/2545/2580>

A sting from thin-tailed scorpions is likely to result in local pain requiring analgesia only.

Clinical features of thick-tailed scorpion stings include:

#### Local effects:

- » immediate and excruciating pain
- » local paraesthesias and hyperaesthesia

#### Systemic effects:

- » tremors, involuntary movements and fasciculations
- » muscle pain, cramps, and weakness

- » generalised paraesthesias and hyperaesthesia
- » excessive sympathetic stimulation e.g. sweating, tachycardia
- » excessive parasympathetic stimulation, e.g. hypersalivation, vomiting, diarrhoea, and priapism
- » bulbar paralysis (dysphagia, dysarthria)
- » respiratory difficulty/failure

### GENERAL MEASURES

- » Observe all cases of thick-tailed scorpion stings for at least 12 hours.
- » Monitor respiratory function.
- » Ventilatory support may be required.

### MEDICINE TREATMENT

Scorpion antivenom therapy is recommended only in cases presenting with systemic neurotoxic effects.

Antivenom available from South African Vaccine Producers (refer to the table above for contact details). See full details in the package insert.

- Scorpion antivenom, IV infusion, 10 mL diluted in 100 mL sodium chloride 0.9% or dextrose 5%, administered over 10 minutes.
  - Response to antivenom may be slow and a repeat dose may be needed.

LoE:IVb

#### CAUTION

Never administer antivenom without being prepared to manage acute anaphylaxis.

Immunisation, primary or booster: (Z23.5)

- Tetanus toxoid vaccine, IM, 0.5 mL, immediately, if not previously immunised within the last 5 years.

In unimmunised or partially immunised patients: (Z23.5)

- Tetanus immunoglobulin, human, IM, 250 units immediately.

### Analgesia

For mild pain:

- Paracetamol, oral, 500mg -1 g 4–6 hourly when required (to a maximum of 4 g in 24 hours)
  - Maximum dose: 15 mg/kg/dose.

LoE:IVb<sup>xii</sup>

Severe local pain:

Application of ice, if tolerated.

- Lidocaine 1–2%, 2 mL: infiltrate affected area as a local anaesthetic.

LoE:IVb<sup>xiii</sup>



**CAUTION**

Opiates increase the risk of respiratory depression and if required, should only be used with caution in severe uncontrolled pain.

**Severe muscle pain and cramps:**LoE:IVb<sup>xiv</sup>

- Calcium gluconate 10%, bolus IV infusion, 10 mL over 10 minutes.
  - Repeat if needed, only once i.e. maximum recommended dose of 2 grams.
  - **Note:** Effect may only last for 20–30 minutes and there is a limited amount that can be given.

LoE:IVb<sup>xv</sup>LoE:IVb<sup>xvi</sup>**19.4 SPIDER ENVENOMATION**

T63.3 + (X21.99)

**DESCRIPTION**

Local venomous spiders are divided into cytotoxic and neurotoxic groups.

To view pictures for the identification of spiders:

<http://www.cmej.org.za/index.php/cmej/article/view/2547/2582>

**Cytotoxic spider group**

The cytotoxic group includes sac, violin, and crab spiders.

Lesions may present with significant bite site necrosis, for which surgical debridement may be required. Bites can take weeks/months to heal.

Note: Antibiotics are reserved for secondary infection.

**Neurotoxic spider group**

The neurotoxic group is represented by the button spider (also known as widow spiders), genus *Latrodectus*. Black button spiders are more venomous than brown button spiders.

Features useful in the identification of the black button spider are:

- » Black or dark brown colour.
- » Variable red markings on the dorsal aspect of the abdomen, which diminish with age. It has no ventral markings.

Features of brown button spider:

- » Light brown to creamy yellow to pitch black in colour.
- » Typical red-orange hourglass-shaped marking on the ventral surface of the abdomen.

Envenomation from black button spiders may cause:

- » Immediate local burning pain and tender regional lymph nodes within an hour.

- » Severe general muscle pain, cramps, and rigidity especially of the large girdle muscles
  - Causes feeling of tightness of the chest and board-like rigidity of a non-tender abdomen.
  - Lasts for days to a week if antivenom is not given.
- » Profuse sweating may be prominent.
- » Diffuse paraesthesia, especially of the hands and feet.

## GENERAL MEASURES

Observe all cases of potential neurotoxic spider bite for at least 24 hours.

## MEDICINE TREATMENT

- » Spider antivenom is only indicated for systemic symptoms of neurotoxicity in patients with button spider bites.
- » Antivenom available from South African Vaccine Producers: (refer to the table above for contact details). See full details in the package insert.
- Spider antivenom, IV infusion, 5–10 mL diluted in 50–100 mL sodium chloride, 0.9% or dextrose 5%, administered over 5–10 minutes. LoE:IVb<sup>xvii</sup>

### CAUTION

Never administer antivenom without being prepared to manage acute anaphylaxis.

### Immunisation, primary or booster: (Z23.5)

- Tetanus toxoid vaccine, IM, 0.5 mL immediately, if not previously immunised within the last 5 years.

### In unimmunised or partially immunised patients: (Z23.5)

- Tetanus immunoglobulin, human, IM, 250 units immediately.

## Analgesia

### For mild pain:

- Paracetamol, oral, 500mg -1 g 4–6 hourly when required (to a maximum of 4 g in 24 hours)
  - Maximum dose: 15 mg/kg/dose.

### Severe muscle pain and cramps:

- Calcium gluconate 10%, bolus IV infusion, 10 mL over 10 minutes.
  - Repeat if needed, only once, i.e. maximum recommended dose of 2 grams.
  - **Note:** Effect may only last for 20–30 minutes and there is a limited amount that can be given.

LoE:IVb<sup>xviii</sup>

### For secondary infection:

See section 4.2: Cellulitis and Erysipelas.

## POISONING

### DESCRIPTION

Frequently encountered poisonings in adults are due to:

- |  |  |
|--|--|
| » analgesics                                     | » ethanol/alcohol                                  |
| » anti-infectives                                | » hydrocarbons e.g. paraffin                       |
| » anticonvulsants                                | » irritants and corrosives                         |
| » antihistamines                                 | » pesticides                                       |
| » cardiodepressants                              | » toxic alcohols e.g. methanol,<br>ethylene glycol |
| » iron   |  |
| » sedatives, antidepressants<br>& antipsychotics |  |

Maintain a high index of suspicion for intentional ingestion in adults presenting with poisoning.

### DIAGNOSTIC CRITERIA

#### Clinical

Clinical presentations due to poisoning can be divided into ‘toxidromes’:

*Anticholinergic:* e.g. antihistamines, amanita pantherina/muscaria, atropine

- |                     |                               |
|---------------------|-------------------------------|
| » fever             | » dry skin and mouth          |
| » ileus             | » blurred vision              |
| » flushing          | » mydriasis (dilated pupils)  |
| » tachycardia       | » coma                        |
| » urinary retention | » hallucinations and seizures |

*Cholinergic:* e.g. organophosphates

- |                            |                 |
|----------------------------|-----------------|
| » salivation               | » diarrhoea     |
| » lacrimation              | » vomiting      |
| » urination                | » bronchorrhoea |
| » miosis (pinpoint pupils) | » bradycardia   |

*Dystonic:* e.g. haloperidol

- |   |                |
|---|----------------|
| » torticollis                                 | » opisthotonos |
| » intermittent spasms and<br>tongue thrusting |                |

*Opiates:* e.g. morphine

- |  |                          |
|--|--------------------------|
| » miosis (pinpoint pupils)             | » decreased bowel sounds |
| » respiratory depression               | » hypothermia            |
| » bradycardia                          | » hypotension            |
| » altered (decreased)<br>consciousness |                          |

*Salicylism:* e.g. aspirin

- |  |             |
|--|-------------|
| » tachypnoea                                   | » agitation |
| » seizures                                     | » coma      |
| » metabolic acidosis and respiratory alkalosis |             |

*Sedative-hypnotic:* e.g. alcohol, benzodiazepines

- » obtundation or coma

*Sympathomimetic:* e.g. cocaine, amphetamines

- » hypertension
- » tachycardia
- » hyperthermia
- » agitation
- » sweating
- » dilated pupils

Sympathomimetic toxidrome partially resembles anticholinergic toxidrome, i.e. fight, flight and fright response, however the sympathomimetic toxic patient is sweaty as opposed to hot dry skin seen with anticholinergic toxicity.

*Toxic alcohols:* e.g. ethylene glycol, methanol

- » metabolic acidosis
- » increased osmolar and anion gaps
- » visual disturbances (methanol)
- » inebriation and depressed level of consciousness.
- » nausea and vomiting
- » tachycardia and arrhythmias
- » renal failure (ethylene glycol)
- » hyperventilation

## GENERAL MEASURES

It is very important to ascertain if a potentially TOXIC DOSE has been taken BEFORE instituting any potentially harmful decontamination procedures in an asymptomatic patient.

- » Take a complete and accurate history, ascertain all relevant facts, and do a complete clinical examination.
- » Maintain a high index of suspicion.
- » Obtain a collateral history, especially for patients with impaired consciousness. A special effort should be made to obtain tablets, packets, containers, etc. to identify agents involved.
- » Stabilise the patient and monitor basic clinical parameters, i.e.:
  - blood pressure and heart rate
  - hydration
  - airway and ventilation
  - neurological status
  - temperature
  - glucose
- » Persistent or prolonged seizures may require medical management. Phenytoin should not be used in cases of poisoning due to substances known to be cardiotoxic e.g. tricyclic antidepressants, or where there is evidence of clinical cardiotoxicity.
- » Prevent physical injury in the restless – avoid excessive sedation.
- » Limit toxicological investigations to those that may influence/alter management. It is important to note the time after ingestion when blood was taken in order to correctly interpret results (e.g. paracetamol and iron levels).

LoE:IVb

## Decontamination

Limit further exposure to poison for the patient and protect healthcare workers where necessary.

### Topical exposure

In the case of skin exposure, remove clothes and wash the body. Showering may be useful.

Remove eye contaminants, especially alkalis, acids and other irritants, by continuous irrigation of the eye with sterile water or normal saline for 15–20 minutes. Analgesic eye drops may be required to perform this adequately.

### Gut decontamination

Methods of gut decontamination include:

- » Gastric lavage
- » Activated charcoal administration
- » Whole bowel irrigation

#### *Gastric lavage*

- » If deemed beneficial, it should only be performed by experienced staff and within 60 minutes of ingestion. LoE:IVb<sup>xxx</sup>
- » Can be considered for cases with:
  - potentially life-threatening ingestions AND
  - a protected airway i.e. fully awake and cooperative or intubated with a depressed level of consciousness.
- » Gastric lavage is contra-indicated after ingestion of corrosive substances and volatile hydrocarbons such as paraffin.
- » Technique:
  - Place patient in left lateral head down position.
  - Insert orogastric tube if possible, with largest bore and rounded tip.
  - Insert 200mL warmed water or normal saline, and aspirate.
  - Continue until recovered solution is clear of particulate matter.

#### *Activated charcoal*

May reduce systemic absorption of a variety of poisonous substances. The greatest benefit is achieved if activated charcoal is given within one hour after ingestion; however, where gastric emptying is delayed by certain substances, there may be a longer period of time in which it is effective. Activated charcoal must only be given in cases where the airway is protected; i.e. fully awake and cooperative patient or intubated with a depressed level of consciousness.

LoE:IVb<sup>xxx</sup>

<b>Activated charcoal may be useful if these poisons are taken in toxic dose</b>	<b>Poisons where charcoal is ineffective and should not be given</b>
<ul style="list-style-type: none"> <li>» carbamazepine, barbiturates, phenytoin</li> <li>» dapsone, quinine</li> <li>» theophylline</li> <li>» salicylates</li> <li>» mushroom poisoning (<i>Amanita phalloides</i>)</li> <li>» slow-release preparations</li> <li>» digoxin</li> <li>» beta-blockers</li> <li>» NSAIDs</li> </ul>	<ul style="list-style-type: none"> <li>» ethanol, methanol, ethylene glycol</li> <li>» brake fluid</li> <li>» petroleum products (e.g. petrol or paraffin)</li> <li>» iron salts</li> <li>» lead, mercury, arsenic</li> <li>» lithium</li> <li>» strong acids or alkalis</li> <li>» other corrosive agents (e.g. household detergents)</li> </ul>

**Table 19.2:** Appropriate use of activated charcoal

- Activated charcoal, oral, 50 g (equivalent to 36 level medicine measures) diluted in 100 mL water.
  - When mixing, add a small amount of water to charcoal in a container.
  - Cap and shake container to make a slurry and then dilute further.
  - Repeated doses of activated charcoal (i.e. 50 g every 4 hours) are effective in enhancing elimination of substances that undergo enterohepatic circulation, e.g. carbamazepine, dapsone, phenobarbitone, quinine or theophylline.

LoE:IIIb<sup>xxi</sup>

### *Whole bowel irrigation*

Whole bowel irrigation can be done for potentially toxic ingestions of substances that are:

- » not absorbed by activated charcoal (e.g. iron and lithium)
- » modified-release and enteric-coated products
- » or for removal of illicit drugs in body packers

Patients must have a protected airway i.e. fully awake and cooperative or intubated with a depressed level of consciousness.

- Polyethylene glycol (PEG) balanced electrolyte solution, NGT, 1500-2000 mL/hour.
  - Continue until rectal effluent is clear.

LoE:IIIb<sup>xxii</sup>

### **Other treatment modalities**

#### Sodium bicarbonate alkalisation

Urine alkalisation enhances renal elimination of certain toxins (salicylates) and serum alkalisation improves acidosis enhancing myocardial functioning (TCAs) and reducing neurotoxicity (salicylates).

This is achieved by administering intravenous sodium bicarbonate ( $\text{NaHCO}_3$ ) to maintain a urinary pH 7.5-8.5 or serum pH 7.45-7.55.

**CAUTION**

This is a high-risk procedure and should only be performed in consultation with a specialist.

**Haemodialysis**

Patients with symptomatically severe poisoning substances including salicylates, lithium, ethylene glycol, methanol, ethanol, and theophylline, may benefit from dialysis (<http://www.extrip-workgroup.org/>).

Refer patient to a hospital with dialysis facilities.

**Antidotes**

There are a limited number of antidotes for poisoning by certain substances, e.g. N-acetylcysteine for paracetamol, naloxone for opioids. Each antidote has specific criteria and indications for use.

Once medically stable:Assess and manage intentional poisoning – self-harm or harm by others:

- » Take a history of circumstances around the poisoning, substance use and mental illness, and examine the mental state.
- » Assess further suicide risk – see Primary Health Care STGs and EML, section 16.7: Suicide risk assessment.
- » Refer to social, psychological and/or psychiatric services.

Assess and manage a substance use disorder:

- » Quantify the amount of substance used and related harms with these rating scales and discuss findings with the patient:
  - ASSIST:[http://www.who.int/substance\\_abuse/activities/assist/en/](http://www.who.int/substance_abuse/activities/assist/en/)
  - DUDIT:<https://www.emcdda.europa.eu/system/files/attachments/12173/DUDIT-English-version.pdf>
- » Provide brief intervention with motivational interview.
- » Refer for rehabilitation.

**REFERRAL**

- » Severely ill patient for ventilatory/circulatory support.
- » Relevant diagnostic testing not available, e.g. paracetamol levels, acid/base assessment.
- » Relevant medication/antidote not available.
- » Dialysis/haemoperfusion required.

## 19.5 ANALGESIC POISONING

### 19.5.1 PARACETAMOL POISONING

T39.1 + (X40.99/X60.99/Y10.99)

#### DESCRIPTION

Liver damage, due to the depletion of glutathione and accumulation of toxic metabolites, can occur in any individual with paracetamol overdose. Patients with predisposing risk factors for hepatotoxicity (“high risk” patients, see below) may experience toxicity at lower ingested doses.

#### Clinical features

Gastrointestinal symptoms (anorexia, nausea, vomiting, malaise) predominate in the first 24 hours. Patients with normal or only slightly raised serum paracetamol levels usually continue to full recovery. In patients with significantly raised paracetamol levels, hepatic toxicity (right upper quadrant abdominal pain and tenderness, elevated bilirubin, raised liver enzymes, coagulation defects, hypoglycaemia, encephalopathy, and metabolic acidosis) may manifest from 20-24 hours, peaking in severity at about 72-96 hours. Patients may make a full recovery in 5-7 days, or demise from hepatic failure, or less commonly, renal failure.

“High risk” patients include those with:

- » Chronic alcoholism
- » Chronic liver disease
- » Use of enzyme-inducing medicines (e.g. carbamazepine, phenytoin, efavirenz, phenobarbitone, rifampicin etc.)
- » Depletion of glutathione resources (e.g. malnutrition, starvation, AIDS, chronic illness, eating disorders etc.)
- » Recent illness, dehydration

#### GENERAL MEASURES

The treatment of paracetamol overdose depends on the dose ingested and the time of presentation since ingestion. A serum paracetamol level is plotted on the nomogram to assess the risk for hepatotoxicity. Values which appear above the treatment line require the antidote N-acetylcysteine (NAC).

#### Acute single ingestion <8 hours post-ingestion:

- » Toxic dose is defined as a paracetamol ingestion >200 mg/kg or 10 g (whichever is less).
- » Give activated charcoal if the patient presents within 1-2 hours of ingestion.
- » Perform a serum paracetamol level and ALT no earlier than 4 hours post-ingestion.
- » If serum paracetamol level results will not be available before 8 hours post-ingestion, AND the patient has taken a toxic dose, do not delay



initiation of NAC. It can always be stopped if the serum level plotted on the nomogram does not indicate its continued use.

### Acute single ingestion >8 hours post-ingestion:

- » Toxic dose defined as >200 mg/kg or 10 g (whichever is less).
- » Start NAC infusion if a toxic dose has been ingested or the patient shows clinical signs of toxicity.
- » Perform serum paracetamol level, ALT, and INR.
- » Indications for continuing NAC infusion:
  - Serum paracetamol level above the treatment line on the nomogram.
  - Serum paracetamol level under the treatment line but abnormal ALT.
  - Measurable paracetamol level and/or abnormal ALT more than 24 hours post-ingestion.

### Acute single ingestion with unknown time of ingestion:

Manage as for >8 hours post-ingestion, however, the nomogram is not applicable to this group.


### Repeated supratherapeutic ingestion (RSTI):

LoE:IIIa<sup>xxiii</sup>

This may occur in patients using repeated high doses of the same product or concurrent use of multiple paracetamol-containing products such as during an acute febrile illness or in patients with chronic pain.

RSTI toxic doses are defined as:

- » >200 mg/kg or 10 g (whichever is less) over a single 24-hour period.
- » >300 mg/kg or 12 g (whichever is less) over a single 48-hour period.
- » >60 mg/kg/day for more than 48 hours **and** patients have symptoms suggestive of liver injury.



Source: Daly FF, Fountain JS, Murray L, Graudins A, Buckley NA; Panel of Australian and New Zealand clinical toxicologists. Guidelines for the management of paracetamol poisoning in Australia and New Zealand—explanation and elaboration. A consensus statement from clinical toxicologists consulting to the Australasian poisons information centres. *Med J Aust.* 2008 Mar 3;188(5):296-301.

**Figure 19.1:** Paracetamol treatment nomogram. (Access the paracetamol nomogram tool on the EML Clinical Guide cellphone application).

## MEDICINE TREATMENT

N-acetylcysteine is the antidote of choice and should be given intravenously. Although it is more effective when given within 8 hours of ingestion of paracetamol, there may be benefit even if liver failure has developed. Histamine may be released, which mimics an allergic reaction. If this occurs and the patient is stable, infusion may continue at a slower rate under antihistamine cover. Stop the infusion if bronchospasm occurs.

- N-acetylcysteine, IV:
  - Initial infusion: 200 mg/kg in 500 mL dextrose, 5% over 4 hours.
  - Second infusion: 100 mg/kg in 1000 mL dextrose, 5% over 16 hours.
  - Any further N-acetylcysteine is given according to the second infusion regimen. LoE:IIIa<sup>xxv</sup>

If N-acetylcysteine IV formulation is unavailable:

- N-acetylcysteine, oral, 140 mg/kg immediately.
  - Followed by 70 mg/kg 4 hourly, for up to seventeen doses. LoE:IIIa<sup>xxvi</sup>

### Note:

- » As anaphylactoid reactions to N-acetylcysteine do occur, the loading dose should preferably be administered in a monitored area. LoE:IVb<sup>xxvii</sup>
- » Avoid giving oral N-acetylcysteine together with activated charcoal as systemic absorption and effect of N-acetylcysteine is reduced. LoE:IIIa<sup>xxviii</sup>

### Further investigations and referral

Blood tests such as renal function, clotting profile, serum glucose and acid/base status should only be done where clinically indicated.

Patients who develop liver failure must be referred for further management and/or possible transplant.

## 19.5.2 SALICYLATE POISONING

T39.0 + (X40.99/X60.99/Y10.99)

### DESCRIPTION

Salicylate poisoning may result from oral and/or topical exposure. Salicylate products vary widely in concentration, e.g. oil of wintergreen is almost 100% methyl salicylate.

### Diagnosis:

Mild to moderate toxicity:

- » Nausea, vomiting, tinnitus, fever, tachypnoea, and respiratory alkalosis

Severe toxicity:

- » Metabolic acidosis, altered mental status, seizures, coma, non-cardiogenic pulmonary oedema.
- » Monitor salicylate levels if possible (do not always correlate with clinical severity):

Severity of toxicity	Peak plasma salicylate concentrations	
	mmol/L	mg/dL
Asymptomatic	<2.2 mmol/L	<30 mg/dL
Mild toxicity	2.2-4.3 mmol/L	30-60 mg/dL
Moderate toxicity	4.3-5.8 mmol/L	60-80 mg/dL
Severe toxicity	>5.8 mmol/L	>80 mg/dL

**Table 19.3:** Severity of toxicity by peak plasma salicylate concentrations.

- » Serial monitoring until declining levels are documented.
- » Monitor and treat hypoglycaemia; patients with normoglycaemia may still be neuroglycopenic.

### GENERAL MEASURES

- » Assess severity with history, clinical examination, and salicylate levels if possible.
- » Correct hydration using dextrose-containing fluids.
- » Ensure hypokalaemia treated early
- » Consider ICU admission for pulmonary and/or cerebral oedema.

### MEDICINE TREATMENT

- Salicylates delay gastric emptying, therefore activated charcoal may be effective for a longer period than usual.
- Whole bowel irrigation maybe useful for enteric-coated or modified-release preparations.

LoE:IIIb<sup>xxx</sup>

#### For mild toxicity:

- » Rehydrate and correct hypovolaemia with dextrose-containing fluids.
  - Add dextrose 50%, 100mL to every litre of balanced crystalloid solution (e.g. ringers lactate) or sodium chloride 0.9%, and administer by IV infusion. LoE:IIIb<sup>xxx</sup>
  - During preparation of the infusion fluid, ensure the equivalent volume of rehydration fluid (e.g. 100mL) is removed from the bag before adding the total dextrose 50% volume (e.g. 100mL).
  - The rate and duration of IV fluids should be guided by clinical assessment of fluid balance. LoE:IVb

#### In patients with moderate to severe toxicity and/or acidosis:

- Sodium bicarbonate 8.4%, IV, 1–2 mL/kg over 30 minutes to manage acidosis. LoE:IIIb<sup>xxxi</sup>
- Simultaneously fluid resuscitate with sodium bicarbonate 8.4%, 150mL added to dextrose 5%, 1L and administer by IV infusion to correct hypovolaemia.
  - During preparation of the infusion fluid, ensure the equivalent volume of dextrose 5% (i.e. 150 mL) is removed from the bag before adding the total sodium bicarbonate 8.4% volume of 150 mL.

- Continue a maintenance infusion at 150 – 200 mL/hour, targeting a urine output of 2mL/kg/hour.
- Titrate the sodium bicarbonate maintenance infusion to a urinary pH of 7.5 – 8.5 and blood pH of 7.45 – 7.5.
- Monitor for and correct hypokalaemia.

LoE:IVb

## REFERRAL

- » Discuss with specialist and consider ICU admission
- » Where acidosis does not respond to sodium bicarbonate, refer for haemodialysis.

LoE:IIIa<sup>xxxii</sup>

### 19.5.3. OPIOID POISONING

T40.0/T40.1/T40.2/T40.3 + (X42.99/X62.99/Y12.99)

## DESCRIPTION

Patients present with the triad of CNS depression, respiratory depression, and constricted pupils. Non-cardiogenic pulmonary oedema can occur.

## GENERAL MEASURES

Supportive management aimed at maintaining cardiorespiratory function.

Body packers/stuffers:

- » Patients may ingest packages of illicit opioids and are at increased risk of life-threatening toxicity in the event of rupture.
- » Abdominal X-rays or CT scan may show packages.
- » Conservative management is recommended, as any attempt at removal risks package rupture.
- » Activated charcoal and whole bowel irrigation may aid in expelling packets.
- » Surgery is reserved for those who develop obstruction or perforation.

## MEDICINE TREATMENT

- Naloxone, IV, 0.4 mg immediately, in patients with significant respiratory depression.
  - Effectiveness is limited by a half-life ( $\pm$  1 hour) that is shorter than most opioids.
  - Repeated incremental doses (e.g.: 0.4 mg, 0.8 mg, 2 mg, 4 mg etc.) may be required at 2 to 3 minute intervals, up to a maximum of 10 mg. If a response is noted, a maintenance infusion of 0.4 mg/hour should be initiated.
  - If there is no response after a maximum total dose of 10 mg of naloxone is administered, the diagnosis of opioid-induced or partial opioid-induced toxicity should be re-assessed.
  - Consider intramuscular or subcutaneous administration if the intravenous route is not available.



- » prolonged QRS >100 msec,
  - » hypotension unresponsive to fluids, or
  - » seizures.
- Sodium bicarbonate 8.4% solution, IV 1–2 mL/kg administered in bolus doses (Specialist consultation).
    - Aim to achieve a serum pH of 7.45–7.55.
    - Monitor acid-base status, serum potassium and sodium.
    - If sodium bicarbonate is unavailable or fluid restrictions limit intake, consider hyperventilation of intubated patients.

LoE:IIIa<sup>xxxv</sup>

In severe cases, inotropic support and anti-arrhythmics may be required (See section 3.3: Cardiac dysrhythmias) in addition to serum alkalinisation. Hypotension is due to myocardial dysfunction and alpha-adrenergic vasodilation; be careful not to fluid overload the patient.

LoE:IVb

For seizures or if sedation is required for restlessness:

Treat with benzodiazepines - see section: 14.4.1 Status epilepticus.

Note: Phenytoin should be avoided (due to potential cardiotoxicity).

LoE:IVb<sup>xxxvi</sup>

Note: Flumazenil is not recommended in any patient with mixed overdoses possibly including tricyclic antidepressants as it increases the risk of convulsions and dysrhythmias.

LoE:Ia<sup>xxxvii</sup>

## 19.7 IRON POISONING

T45.4 + (X44.99/X64.99/Y14.99)

### DESCRIPTION

Iron is a commonly prescribed drug, especially in pregnancy, and in overdose causes initial gastrointestinal toxicity. Patients may have a stage of “apparent recovery” 6–36 hours post-ingestion. This should not be confused with true recovery as patients may subsequently deteriorate.

Significant exposure may be associated with:

- » severe vomiting and diarrhoea
- » metabolic acidosis,
- » CNS depression,
- » hepatitis.
- » gastrointestinal haemorrhage
- » hypotension, shock
- » renal failure, and

Ferrous salt	Amount	Elemental iron
Ferrous sulphate	170 mg	± 65 mg
Ferrous gluconate	300 mg	35 mg
Ferrous fumarate	200 mg	± 65 mg

**Table 19.4:** Elemental iron content available in different iron salts

## GENERAL MEASURES

- » Gastrointestinal decontamination by whole bowel irrigation is recommended:
  - if >60 mg/kg elemental iron has been ingested
  - if modified-release preparations ingested
  - undissolved tablets still visible on abdominal X-ray
- » Activated charcoal does not bind iron and is not indicated in isolated iron overdose.
- » Serum iron concentration should be measured 4–6 hours after ingestion and repeated every 6 hours until peak. The use of deferoxamine (desferrioxamine) interferes with the interpretation of further serum iron levels.
- » Give intravenous fluids for hypotension.

## MEDICINE TREATMENT

### Chelation therapy

- » Patients with serum iron levels <54 µmol/L and absence of symptoms >6 hours after overdose do not require chelation therapy.
- » Deferoxamine (desferrioxamine) may be used for the following indications (if in doubt, consult the Poisons Information Helpline):
  - Severe symptoms (altered mental status, haemodynamic instability, metabolic acidosis).
  - Serum iron concentration >90 µmol/L.
  - Peak serum iron concentration >60 µmol/L, AND persistent gastrointestinal symptoms.

LoE:IIIa<sup>xxxviii</sup>

- Deferoxamine (desferrioxamine), IV infusion, 80 mg/kg.
  - Administer at 15mg/kg/hour over about 6 hours.
  - Beware of hypotension.
  - **Note:** Prolonged use (>24 hours) of high doses are associated with acute lung injury and should be avoided. However, additional doses may be required in severe poisonings – A benefit-risk assessment is required in these patients.
  - Where IV access is not obtainable, deferoxamine can be given by IM injection as follows: deferoxamine, IM injection 1 g immediately, followed by 500 mg every 4 to 12 hours, as needed based on clinical response.
  - For cardiogenic shock, the IV route is preferred and should be used as soon as IV access is possible.
  - Deferoxamine can be used in pregnant women.

LoE:IVb<sup>xxxx</sup>

LoE:IIIa<sup>xl</sup>

## REFERRAL

Haemodialysis may be needed to remove deferoxamine-iron complexes in patients with renal insufficiency.

## 19.8 THEOPHYLLINE POISONING

T48.6 + (X44.99/X64.99/Y14.99)

### DESCRIPTION

Patients present with:

- » tachycardia and tachyarrhythmias,
- » nausea and vomiting
- » agitation
- » seizures
- » hyperventilation
- » tremor
- » profound hypokalaemia

### GENERAL MEASURES

- » Monitor ECG and treat dysrhythmias.
- » Monitor and correct fluid status and electrolyte abnormalities.
- » Monitor theophylline concentrations, if available. Levels may continue to rise up to 24 hours after ingestion of modified release preparations.

### MEDICINE TREATMENT

- Activated charcoal, oral, 50 g diluted in 100 mL water.
  - Multiple doses of activated charcoal enhance elimination.

LoE:IIIa<sup>xii</sup>

Vomiting is common: (R11)

- Metoclopramide, IV/oral, 10 mg 8 hourly as required.

LoE:IVb

Correct hypokalaemia cautiously: E87.6 + (T48.6+X44.99/X64.99/Y14.99)

- Potassium chloride, IV, 20-40 mmol/L in sodium chloride, 0.9%
  - Maximum rate of infusion: 20 mmol/hour.

LoE:IIIa<sup>xiii</sup>

For seizures: R56.8 + (T48.6+X44.99/X64.99/Y14.99)

Treat with benzodiazepines - see section: 14.4.1 Status epilepticus.

**Note:** Phenytoin should be avoided (due to potential cardiotoxicity).

LoE:IVb<sup>xiii</sup>

### REFERRAL

In patients with symptoms of severe overdose (severe hypokalaemia, seizures, refractory hypotension, dysrhythmias, theophylline level >555 µmol/L (100 mg/L), refer for haemodialysis.

LoE:IIIa<sup>xiv</sup>

## 19.9 SEDATIVE HYPNOTIC POISONING

### 19.9.1 BENZODIAZEPINE POISONING

T42.4 + (X41.99/X61.99/Y11.99)

### DESCRIPTION

Patients present with depressed levels of consciousness, confusion, ataxia, and dysarthria. Benzodiazepines are unlikely to cause significant respiratory



depression unless co-ingested with alcohol or other CNS depressants. However, there is a risk of respiratory depression due to overdose in the elderly.

## GENERAL MEASURES

Management is supportive, and ventilation may be required.

Note: The use of flumazenil is not recommended in any patient with possible benzodiazepine poisoning as it increases the risk of convulsions and dysrhythmias.

LoE: Ia<sup>xiv</sup>

### 19.9.2 LITHIUM POISONING

T43.8 + (X41.99/X61.99/Y11.99)

#### DESCRIPTION

Lithium toxicity mostly occurs with chronic therapy and may be precipitated by decreased excretion due to renal dysfunction, diuresis, dehydration, hyponatraemia, or drug-drug interactions (e.g. NSAIDs, diuretics, ACE-inhibitors, and ARBs).

#### Signs and symptoms include:

- » nausea, vomiting, and diarrhoea
- » nystagmus
- » CNS symptoms: tremor, hyperreflexia, choreoathetoid movements, fasciculations, ataxia, agitation, confusion and lethargy

#### In severe toxicity:

- » Coma
- » Seizures
- » Dysrhythmias
- » Hypotension

## GENERAL MEASURES

Monitor:

- » Vitals signs, mental status, and urine output.
- » If available, do serial lithium levels 6 hourly until peaked and declining.
- » Electrolytes and renal function.
- » Cardiac function and treat dysrhythmias (see chapter 3.3: Cardiovascular dysrhythmias).
- » Thyroid function, in chronic toxicity.

## MEDICINE TREATMENT

If ingested dose is potentially toxic or modified-release products were ingested, consider WBI.

LoE: IIIb<sup>xlvi</sup>

- » Hydration: administer sodium chloride, 0.9 % to maintain urine flow of 1–2 mL/kg/hour while preventing hypernatremia.

- » Correct electrolyte abnormalities: see section: 7.2 Major electrolyte abnormalities.
- » For seizures: Treat with benzodiazepines – see section: 14.4.1 Status epilepticus.

Note: Phenytoin should be avoided (due to potential cardiotoxicity).

LoE: I**b**<sup>xvii</sup>

## REFERRAL

Early referral for haemodialysis is indicated in severe lithium poisoning and in patients with renal impairment. Discuss with a specialist.

LoE: III**a**<sup>xviii</sup>

## 19.10 ISONIAZID POISONING

T37.1 + (X44.99/X64.99/Y14.99)

### DESCRIPTION

Acute toxicity can present with the classic triad of seizures, metabolic acidosis, and coma. Seizures are of a generalised tonic-clonic type, and often refractory to standard anticonvulsant therapy.

### GENERAL MEASURES

Supportive management aimed at preventing and managing complications. Treat hyperthermia.

### MEDICINE TREATMENT

For seizures:

- Pyridoxine, crushed tablets orally or via NGT in unconscious patient(s).
  - Known amount: Pyridoxine dose is 1 g for every gram of isoniazid ingested (maximum of 5 g)
  - Unknown amount: Pyridoxine dose is 5 g for unknown amount ingested.

LoE: III**a**<sup>xlix</sup>

Benzodiazepines may be used as an interim measure to control seizures:

- Lorazepam, IV/IM, 4 mg, repeat once after 5–10 minutes, if necessary.

LoE: I**b**<sup>j</sup>

**OR**

- Diazepam, IV, 10 mg, not faster than 2 mg/minute, repeat once after 5-10 minutes if necessary.

**OR**

- Clonazepam, IV, 2 mg, repeat once after 5–10 minutes if necessary.

**OR**

- Midazolam, IM/IV 10 mg, repeat once after 5–10 minutes if necessary.

**OR**

- Midazolam buccal, 10 mg using the parenteral formulation.

**CAUTION**

Phenytoin should not be used to control seizures in INH poisoning, as it does not have GABA agonist properties.

LoE:IVb<sup>ii</sup>**REFERRAL**

- » Uncontrolled seizures

## 19.11 CALCIUM CHANNEL BLOCKER AND BETA BLOCKER POISONING

T44.7/T46.1 + (X43.99/X63.99/Y14.99)

**DESCRIPTION**

Cardiovascular toxicity results in profound hypotension, bradycardia, decreased systemic vascular resistance and cardiogenic shock. Depressed level of consciousness and metabolic acidosis are due to poor tissue perfusion. Hyperglycaemia and hypokalaemia may occur. Patients who have co-ingested other cardiac medicines and those with pre-existing cardiac disease are at increased risk of morbidity.

The treatment of suspected cardiogenic shock in calcium channel blocker and beta blocker poisoning follows similar therapeutic principles. The mainstay of treatment is high-dose insulin euglycaemic therapy (HIET) and inotrope and vasopressor infusions.

LoE:IVb<sup>iii</sup>**GENERAL MEASURES**

- » Monitor vital signs, ECG, and blood glucose.
- » Treat symptomatic patients in consultation with a specialist.

**MEDICINE TREATMENT**

- » Caution is advised for all decontamination procedures as they increase vagal tone and may exacerbate bradycardia.
- » Activated charcoal may be considered before the onset of symptoms.
- » Whole bowel irrigation can be considered for ingestion of modified-release preparations.

LoE:IIIa<sup>iii</sup>

**Bradycardia:** R00.1 + (T46.1/X44.99/X64.99/Y14.99)

- Atropine, IV 0.5–1 mg every 2–3 minutes to a maximum of 3 mg.

LoE:IVb<sup>iv</sup>

**Hypotension:** I95.9 + (T46.1/X44.99/X64.99/Y14.99)

- Start with sodium chloride 0.9%, IV.

LoE:IVb<sup>iv</sup>

**If not effectively controlled**

**ADD**

- Calcium gluconate 10%, IV, 30–60 mL given over 15–30 minutes, with ECG monitoring.

- This may be repeated a maximum of 4 times. *LoE:IVb<sup>vi</sup>*
- Simultaneously use vasopressors and inotropes as needed, e.g. adrenaline (epinephrine) infusion for persistent hypotension (section 20.1: Cardiac arrest in adults) or dobutamine for bradycardia (section 20.11.3: Cardiogenic shock) and refer patient immediately.

## REFERRAL

All patients requiring HIET should be treated in a High Care or ICU setting

## 19.12 COTRIMOXAZOLE POISONING

T37.0 + (X44.99/X64.99/Y14.99)

### DESCRIPTION

Acute overdose is associated with a low probability of clinically relevant toxicity. Symptoms include nausea and vomiting, dizziness, headache, and neurological symptoms (such as drowsiness, confusion, and mental depression). Other signs include bone marrow depression, haematuria, and renal insufficiency. Hypersensitivity reactions may occur.

### GENERAL MEASURES

- » Treatment is symptomatic and supportive.
- » Monitor FBC, electrolytes, glucose, hepatic, and renal function in symptomatic patients.

## 19.13 ANTIRETROVIRAL AGENTS POISONING

T37.5 + (X44.99/X64.99/Y14.99)

### DESCRIPTION

- » Limited data is available regarding overdose of these medicines.
- » Toxicological effects are generally extensions of their adverse effects.

### GENERAL MEASURES

- » Monitor FBC, serum electrolytes, renal and liver function.
- » Monitor serum lipase in patients with abdominal pain.
- » Lactic acid and serum pH should be monitored in acidotic patients.

### TREATMENT

- » There are no specific antidotes.
- » Treatment is symptomatic and supportive.

## 19.14 ILLICIT DRUGS

### 19.14.1 COCAINE POISONING

T40.5 + (X42.99/X62.99/Y12.99)

#### DESCRIPTION

Cocaine may be absorbed through any mucous membrane, smoked, ingested, or injected intravenously.

#### Clinical features:

Mild toxicity: euphoria, anxiety, altered mental status, tachycardia, mild hypertension.

Moderate toxicity: agitation, paranoia, hallucinations, cardiac dysrhythmias.

Severe toxicity: severe headache, seizure, hyperthermia, rhabdomyolysis, severe acidosis, vascular incidents (stroke, MI, intestinal ischaemia etc.), pulmonary oedema.

#### GENERAL MEASURES

- » Supportive management aimed at preventing and managing complications.
- » Cool patients with hyperthermia.
- » Raised serum creatinine kinase may indicate rhabdomyolysis or myocardial infarction.
- » Body packers/stuffers:
  - Patients may ingest packages of cocaine and are at increased risk of life-threatening toxicity in the event of rupture.
  - Abdominal X-rays or CT scan may be helpful in identifying packages.
  - Conservative management is recommended, as any attempt at removal risks package rupture.
  - Activated charcoal and whole bowel irrigation may aid in expelling packets.
  - Surgery is reserved for those who develop obstruction or perforation.

#### MEDICINE TREATMENT

Benzodiazepines play a key role in the management of sympathetic and psychomotor features of cocaine poisoning.

#### For sedation and seizures:

Treat with benzodiazepines - see section: 14.4.1 Status epilepticus.

**Note:** Phenytoin should be avoided (due to potential cardiotoxicity).

LoE: IVb<sup>vii</sup>

#### Delirium with severe agitation:

See section 20.8: Delirium with perceptual disturbances.

**Arrhythmias:**

See section 3.3: Cardiac dysrhythmias.

**Hypertension unresponsive to benzodiazepines:**

See section 3.6.1: Hypertension, severe.

**CAUTION**

β-blockers (other than labetalol) may worsen vasoconstriction and should not be used.

**19.14.2 AMPHETAMINE DERIVATIVES POISONING**

T43.6 + (X41.99/X61.99/Y11.99)

**DESCRIPTION**

These include:

- » “Ecstasy”: 3,4-methylenedioxymethamphetamine (MDMA).
- » “Ice” and “Eve”: 3,4-methylenedioxy-N-ethylamphetamine (MDEA).
- » “Tik”: Methamphetamine.

Drug effects are due to the increased release of noradrenaline, dopamine, and serotonin. Patients present with:

- |   |                     |
|---|---------------------|
| » hyperthermia, especially with MDMA        | » sweating          |
| » tachycardia                               | » dilated pupils    |
| » hypertension                              | » teeth grinding    |
| » angina pectoris and myocardial infarction | » delirium          |
| » stroke                                    | » tremors           |
| » hyperactivity                             | » seizures and coma |

Additional complications include:

- |                          |                 |
|--------------------------|-----------------|
| » rhabdomyolysis         | » hyponatraemia |
| » hyperkalaemia          | » dehydration   |
| » acute tubular necrosis |                 |

**GENERAL MEASURES**

Supportive management aims to maintain stable cardiorespiratory function. Manage hyperthermia, hypoglycaemia, dehydration, and electrolyte abnormalities.

**MEDICINE TREATMENT**

For seizures: R56.8 + (T43.6 + X41.99/X61.99/Y11.99)

LoE:IVb<sup>viii</sup>

Treat with benzodiazepines - see section 14.4.1: Status epilepticus.

**Note:** Phenytoin should be avoided (due to potential cardiotoxicity).

**Severe hypertension:**

See section 3.6.1: Hypertension, severe.

Haemodialysis may be required for acute renal failure.

## 19.15 HYDROCARBON POISONING

T52.0 + (X46.99/X66.99/Y16.99)

**Note:** This section does not include information on aromatic hydrocarbons (e.g. benzene, toluene, xylene) often used by glue sniffers to get high.

### DESCRIPTION

Poisoning due to petroleum products, including paraffin, turpentine, petrol, and mineral spirits.

Clinical signs include:

- » chemical pneumonitis
- » arrhythmias
- » nausea and vomiting
- » depression, seizures, coma

### GENERAL MEASURES

- » If contaminated, remove clothing and wash skin.
- » Do not induce emesis or attempt gastric emptying/lavage.

### MEDICINE TREATMENT

- » Activated charcoal is of no value.
- » Observe and examine for chemical pneumonitis. Prophylactic antibiotics are not indicated.

## 19.16 INGESTION OF CAUSTIC SUBSTANCES

T54.1A/T54.2/T54.3/T54.9 + (X46.99/X66.99/Y16.99)

### DESCRIPTION

- » Alkaline: Toilet bowl cleaners, drain cleaners, oven cleaners.
- » Acids: Various e.g. domestic descalers.
- » Caustic substances can cause necrosis of the gut mucosa and underlying tissue, resulting in acute perforation (particularly strong alkalis), and possible strictures later (which can occur with acids and alkalis). Concentrated caustic substances are more corrosive and present a higher risk for necrosis.

### GENERAL MEASURES

- » No activated charcoal, forced emesis, or gastric lavage.
- » Rinse mouth with copious amounts of cold water.
- » Make patient nil by mouth and set up IV access.
- » If persistent vomiting, drooling or any difficulty in swallowing, patient may require endoscopic evaluation within 24-48 hours and possible surgical intervention. (Discuss with a specialist).

LoE:lvb<sup>ix</sup>

## 19.17 ALCOHOLS

### 19.17.1 ETHANOL POISONING

T51.0 + (X45.99/X65.99/Y15.99)

#### DESCRIPTION

Acute poisoning usually presents with:

- » Nausea and vomiting
- » Hypoglycaemia
- » Hypokalaemia
- » Depression, seizures, coma
- » Hypothermia
- » Acidosis

Consider other causes for the patient's condition, including hypoglycaemia and head trauma.

#### GENERAL MEASURES

- » Supportive management is aimed at maintaining stable cardiorespiratory function.
- » Protect the airway (ventilation may be needed).
- » Manage hypothermia, hypoglycaemia, and electrolyte abnormalities.

#### MEDICINE TREATMENT

- Thiamine, IV, 100 mg in 1 L dextrose, 5%.

### 19.17.2 ETHYLENE GLYCOL POISONING

T52.3 + (X46.99/X66.99/Y16.99)

#### DESCRIPTION

Ethylene glycol is the main component of motor vehicle radiator coolant/antifreeze and is occasionally found in brake fluid. It is also found in homemade toilet and drain cleaners.

Mild to moderate intoxication: resembles alcohol intoxication, with nausea and vomiting, nystagmus, ataxia, and somnolence.

Severe intoxication: associated with more severe CNS depression (coma, hypotonia, hyporeflexia) and high anion gap metabolic acidosis. Cardiovascular signs include tachycardia and hypertension. Calcium oxalate crystals cause renal failure and hypocalcaemia, which may manifest with prolongation of the QT interval on ECG or tetany.

$$\text{Anion gap} = \text{Na} - (\text{Cl} + \text{HCO}_3) [\text{Normal} = 8 - 16]$$

#### GENERAL MEASURES

- » Consult the Poisons Information Helpline for assistance with management.
- » Treat early to reduce the risk of forming toxic metabolites.



- » Monitor blood gases and administer sodium bicarbonate.
- » Early haemodialysis is the treatment of choice for severe poisoning with profound acidosis.

## MEDICINE TREATMENT

### Ethanol

#### Indications:

LoE: Ivb <sup>x</sup>
-----------------------

History of ingestion, plus any two of the following criteria:

- » Arterial pH <7.3
- » Serum bicarbonate <20 mmol/L
- » Presence of urinary oxalate crystals (ethylene glycol only) or visual disturbances (methanol only)

#### Preparation and administration of ethanol:

#### Step 1: Prepare an ethanol 20% solution:

##### If using Ethanol 96% BP, oral,

- Add 1 part ethanol 96% to 4 parts juice or water e.g. 250 mL of ethanol 96% with 1000mL water or juice to give a total volume of 1250 mL ethanol 20%.

##### If using Ethanol 40% v/v (gin, whiskey, vodka), oral

- Add 1 part ethanol 40% to 1 part juice or water e.g. dilute 500mL of ethanol 40% with 500mL water or juice to give a total volume of 1000mL ethanol 20%.
- **Note:** Spirit liquor products in South Africa are frequently bottled at 43% v/v. These can be used interchangeably.

#### Step 2: Administer a loading dose:

- Ethanol 20% (the solution prepared in Step 1), oral, 4 mL/kg over 15-30 minutes.

#### Step 3: Continue with maintenance doses:

- Ethanol 20% (the solution prepared in Step 1), oral:
  - Non-drinker: 0.5 mL/kg/hour
  - Chronic drinker: 1 mL/kg/hour

### WORKED EXAMPLES

For a 60kg patient who is a non-drinker:

**Loading dose:** 240 ml of the ethanol 20% solution orally over 15-30 minutes.

**Maintenance dose:** 30 mL per hour orally of the ethanol 20% solution.

For a 60kg patient who is a chronic drinker:

**Loading dose:** 240 ml of the ethanol 20% solution orally over 15-30 minutes.

**Maintenance dose:** 60 mL per hour orally of the ethanol 20% solution.

#### Note:

- » If patients are not co-operative, administer ethanol via a nasogastric tube.

**CAUTION**

Locally available commercial ethanol products are not approved for IV administration and should not be administered via this route.

- » Maintain ethanol levels of 1–1.3 g/L (100–130 mg/dL).
- » Where ethylene glycol, methanol (see Section 19.17.3: Methanol poisoning), and ethanol levels are not available for monitoring purposes, titrate the ethanol rate of administration according to improvement in metabolic acidosis and signs of systemic toxicity.
- » Increase the dose of ethanol if the patient is receiving concomitant haemodialysis.
- » Several days of ethanol therapy may be required until clinical condition improves.
- » Alcoholic beverages are sometimes labelled as "percentage proof". Alcohol proof values are double the alcohol percentage (volume/volume) values. i.e. an 80 proof alcohol would be 40% (v/v).

LoE:IVb<sup>xi</sup>

**Cofactor therapy:**

- Thiamine, oral, 100 mg daily.
- Pyridoxine, oral, 100 mg daily.

LoE:IVb<sup>xii</sup>

**Metabolic acidosis:** E87.2 + (T52.8/X46.99/X66.99/Y16.99)

- Sodium bicarbonate 8.4%, IV, 50–100 mmol/L administered over 30–45 minutes.

**Note:**

- » Rapid correction of acidosis may precipitate seizures in a hypocalcaemic patient. Correct severe or clinically evident hypocalcaemia.
- » Monitor glucose levels and correct hypoglycaemia, if necessary.

LoE:IVb<sup>xiii</sup>

**REFERRAL**

Severe poisoning with profound acidosis for early haemodialysis.

**19.17.3 METHANOL POISONING**

T51.1 + (X45.99/X65.99/Y15.99)

**DESCRIPTION**

Methanol, once present in methylated spirits, was replaced with less toxic agents 10–20 years ago. However, it may still be found in stove or model fuels, as well as in antifreeze and windscreen washes.

**Presentation:**

- » Ingestion of methanol results in initial mild inebriation (headache, confusion, nausea, and vomiting) similar to ethanol intoxication followed by an asymptomatic/latent period.

- » After a latent period of about 12-24 hours, toxic metabolite (formic acid) formation results in severe high anion gap metabolic acidosis, and retinal toxicity (from visual impairment to total blindness).

$$\text{Anion gap} = \text{Na} - (\text{Cl} + \text{HCO}_3) [\text{Normal} = 8 - 16]$$

## MEDICINE TREATMENT

If acidotic or patient has visual disturbances:

Start with immediate ethanol antidote therapy (See section 19.17.2: Ethylene glycol poisoning), and evaluate for urgent dialysis, if available.

LoE:IIIa<sup>xiv</sup>

## 19.18 PESTICIDES AND RODENTICIDES

### 19.18.1 AMITRAZ POISONING

T44.4 + (X43.99/X63.99/Y13.99)

\* Notifiable condition.

Poisoning from all pesticides (i.e. agricultural stock remedies) is a notifiable medical condition. Please visit

<https://nicd.ac.za/nmc-overview/notification-process> for further information.

## DESCRIPTION

Amitraz is a pesticide/insecticide with  $\alpha_2$ -adrenergic agonist properties. It is usually formulated as a tick dip for dogs, cattle, and sheep. Commercial formulations contain up to 20% of amitraz in organic solvents. Poisoning may occur when amitraz is ingested or absorbed via the skin or by inhalation.

A history of an unspecified rat poison or pesticide exposure warrants consideration of other active ingredients such as super-warfarin anticoagulants and organophosphates.

Patients with acute poisoning present with:

- » impaired consciousness
- » drowsiness
- » vomiting
- » hypotension
- » constricted pupils or rarely, dilated pupils
- » bradycardia
- » respiratory depression
- » hypothermia
- » generalized seizures

Other complications include:

- » hyperglycaemia
- » glycosuria
- » mild increase in transaminases

Patients usually regain consciousness within 24 hours.

**Note:** Amitraz poisoning can be confused with organophosphate poisoning; whilst amitraz causes central nervous system depression, bradycardia, miosis and respiratory depression, it does not cause excessive sweating and salivation, urinary and faecal incontinence or muscle fasciculation which are seen with organophosphate poisoning. Furthermore, organophosphate toxicity results in reduced serum pseudocholinesterase levels.

### GENERAL MEASURES

- » Decontamination of skin and clothes where applicable.
- » Supportive and symptomatic treatment to maintain patent airway, adequate respiration and circulation.
- » Mechanical ventilation may be needed in some cases.
- » Keep patient warm.

### MEDICINE TREATMENT

- Activated charcoal, once patient is stabilised.

For severe bradycardia: R00.1 + (T44.4 + X43.99/X63.99/Y13.99)

Manage with atropine - see section 3.3.3: Heart block (second or third degree).

For seizures: R56.8 + (T44.4 + X43.99/X63.99/Y13.99)

Treat with benzodiazepines - see section: 14.4.1 Status epilepticus.

**Note:** Phenytoin should be avoided (due to potential cardiotoxicity).

LoE:IVb<sup>xv</sup>

## 19.18.2 ORGANOPHOSPHATE POISONING

T60.0 + (X48.99/X68.99/Y18.99)

\* Notifiable condition.

Poisoning from all pesticides (i.e. agricultural stock remedies) is a notifiable medical condition. Please visit

<https://nicd.ac.za/nmc-overview/notification-process> for further information.

### DESCRIPTION

Absorption may occur through the skin, gastrointestinal tract if taken orally, or by inhalation.

Patients present with muscarinic and nicotinic manifestations of intoxication.

- » Peripheral effects:
  - *Muscarinic overstimulation:* bradycardia, hypotension, salivation, lacrimation, vomiting, diarrhoea, increased bronchial secretions, bronchospasm, and miosis (pinpoint pupils).
  - *Nicotinic overstimulation:* muscle weakness and fasciculations, tachycardia, hypertension, mydriasis (dilated pupils).
- » Central effects: coma, confusion, convulsions.

Diagnosis is supported by low serum pseudocholinesterase levels.

Intermediate syndrome can occur within 1-4 days after recovery from cholinergic crisis. Patients develop weakness or paralysis predominantly affecting the muscles of respiration (including the neck flexors and bulbar muscles) and proximal limb muscles, sparing the distal muscles. Cranial nerves may also be affected. Supportive care is the mainstay of therapy.

LoE:IIIa<sup>bxvi</sup>

### CAUTION

A history of an unspecified rat poison or pesticide exposure warrants consideration of other active ingredients such as super-warfarin anticoagulants and amitraz.

## GENERAL MEASURES

- » Ensure use of personal protective equipment for staff – gloves, gowns, and eye protection. If staff come into contact with body fluids, wash off immediately.
- » Decontamination procedures for the patient should only be done once the patient is fully resuscitated.
- » Remove patient's clothes and wash the body with soap and water. Place clothes in closed bags.
- » Maintain adequate ventilation and circulation. Ventilatory support in ICU may be required. Suction secretions frequently.
- » Note: If using suxamethonium for intubation, consider that metabolism may be delayed and prolonged respiratory support may be required. Use alternative agents if possible (See section 12.3: Muscle relaxants).

LoE:IIIa<sup>bxvii</sup>

## MEDICINE TREATMENT

- Activated charcoal, once patient is stabilised.

For bronchorrhoea, bronchospasm, or bradycardia:

LoE:IIIa<sup>bxviii</sup>

- Atropine bolus, IV, 2 mg.
  - Reassess after 3–5 minutes for evidence of atropinisation as indicated by reduced bronchial secretions, dry skin, increasing heart rate and blood pressure, and dilating pupils (note: pupil dilatation may be delayed).
  - Give repeated atropine boluses incrementally doubling the dose until adequate clinical response achieved, e.g. 2 mg, 4 mg, 8 mg, 16 mg etc.
    - If no clinical response, give double the dose.
    - If some response, give the same or reduced dose.
- Follow atropinisation with atropine, IV infusion.
  - Titrate according to clinical response, starting at 10% of the total bolus dose. Calculate the total dose of atropine given as boluses (as described above). Give 10–20% of this dose per hour, titrating according to clinical response.

- e.g.: 40 mg of Atropine in 200 mL sodium chloride 0.9% (0.2 mg/mL)  
10-20 mg/hour = 50-100 mL/hr.
- o Reassess frequently and adjust atropine infusion as follows:
  - Bronchial secretions, bronchospasm or bradycardia recurs: increase dose.
  - Good control of bronchial secretions and signs of atropine overdose (tachycardia, mydriasis, agitation, pyrexia, reduced bowel sounds and urinary retention): decrease dose.
  - No recurrence of bronchial secretions and no signs of atropine overdose: reduce dose slowly.

**Note:**

- » Do not stop atropine infusion abruptly; instead, wean over at least 24 hours.
- » Tachycardia and mydriasis are not contraindications for giving atropine in the acute resuscitation setting.

LoE:IIIa<sup>xxx</sup>For severe agitation:

- Diazepam, IV, 5–10 mg, immediately.
  - o Repeat after 30–60 minutes if needed.

LoE:IIIa<sup>xxx</sup>**REFERRAL**

Refer if ventilatory support is unavailable.

**19.18.3 PARAQUAT POISONING**

T60.3 + (X48.99/X68.99/Y18.99)

\* Notifiable condition.

Poisoning from all pesticides (i.e. agricultural stock remedies) is a notifiable medical condition. Please visit

<https://nicd.ac.za/nmc-overview/notification-process> for further information.

**DESCRIPTION**

Paraquat is the most toxic herbicide known, and toxicity causes multi-organ failure which is often fatal. Following oral ingestion, patients present with oral, oesophageal, and gastric erosions with severe gastroenteritis. Multi-organ failure develops within 1–3 days, particularly renal and respiratory failure. Patients surviving the initial phase usually develop pulmonary fibrosis.

**GENERAL MEASURES**

- » Supportive and symptomatic management to maintain patent airway, adequate respiration, and circulation.
- » Mechanical ventilation may be needed in some cases.
- » Palliative care is the mainstay of treatment.

**CAUTION**

High inspiratory fraction of inspired oxygen (FiO<sub>2</sub>) may worsen pulmonary toxicity. Supplemental oxygen should only be provided if the patient is confirmed hypoxic.

**MEDICINE TREATMENT**

- Activated charcoal

**19.19 ANTICOAGULANT (WARFARIN AND RODENTICIDE SUPERWARFARIN) POISONING**

T45.5 + (X44.99/X64.99/Y14.99)

\* Notifiable condition – rodenticide superwarfarin poisoning

Poisoning from all pesticides (i.e. agricultural stock remedies) is a notifiable medical condition. Please visit

<https://nicd.ac.za/nmc-overview/notification-process> for further information.

**DESCRIPTION**

Poisoning due to ingestion of warfarin and superwarfarins, e.g. rat poison and other vermin poisons. Warfarin toxicity can occur with either acute overdose or unintentionally, during therapeutic use, whereby drug interactions increase warfarin bioavailability (e.g. concomitant enzyme inhibitor), or concomitant anticoagulant drugs are administered (e.g. NSAIDS). Bleeding is the main clinical presentation e.g. gastrointestinal or intracranial bleeding; however bleeding may be occult. Superwarfarins are more potent than warfarin and may have a long duration of effect; small doses of concentrated formulations may cause significant anticoagulation.

**CAUTION**

Where the history is of an unspecified rat poison or pesticide ingestion, consider other active ingredients such as amitraz and organophosphates.

**GENERAL MEASURES**

- » Resuscitation.
- » Stop warfarin in patients on therapy.
- » Measure INR at baseline and 48 hours post ingestion, as the anticoagulant effect may be delayed by 1–2 days.

**MEDICINE TREATMENT**

Do NOT give vitamin K<sub>1</sub> prophylactically. It is only indicated when there is active bleeding or a specifically raised INR (INR > 4).

**Active bleeding:**

R58 + (T45.5 + X44.99/X64.99/Y14.99)

- Lyophilised plasma, IV, 15 mL/kg.

**OR**

- Fresh Frozen Plasma, IV, 15 mL/kg.

LoE:IIIa<sup>xxi</sup>

**AND**

- Vitamin K<sub>1</sub>, IV, 10 mg
  - Administer as a slow IV injection.
  - Do not dilute or mix with other injectables.

For patients on long term vitamin K antagonist anticoagulants, e.g. warfarin:

- Temporarily discontinue anticoagulant therapy.
- Decrease Vitamin K dose by half, i.e. Vitamin K<sub>1</sub>, IV, 5 mg.  
Administer as a slow IV injection.

LoE:IV

**No bleeding but INR is raised (INR > 4):**

**Note:** If Vitamin K<sub>1</sub> is only available as a parenteral preparation, administer the same preparation orally as this is safest in anticoagulant poisoning.

Patients NOT on long-term therapeutic anticoagulants and INR > 4.0:

- Vitamin K<sub>1</sub>, oral, 10-20 mg.
  - Check INR at least 12 hours after vitamin K<sub>1</sub> has been administered. Repeated doses should be guided by further INR (or PT) measurements every 4-6 hours until the patient is stable, and thereafter, every 24 hours. INR (or PT) levels may take 3-4 days to normalise.

Patients on long-term vitamin K antagonist anticoagulant drugs (e.g. warfarin therapy):**If INR 5-8:**

- Temporarily discontinue any anticoagulant treatment.

**If INR > 8:**

- Vitamin K<sub>1</sub>, oral, 0.5 – 1.0 mg (one tenth of the normal dose).
  - A repeat dose may be given 12-24 hrs later if the INR remains ≥ 8.

**Note:**

- » These patients are complex and require management in consultation with a haematologist.
- » Patients with prosthetic heart valves receiving high-dose vitamin K have a higher risk for increased resistance to warfarin and development of thromboembolism. Treat as above but monitor INR frequently to prevent overcorrection. Treat in consultation with a specialist.
- » For patients on other anticoagulant therapies, additional antagonists may be required.
- » In all patients on therapeutic warfarin, a major overdose or bleeding episode should prompt careful review of the need for anticoagulation.
- » Warfarin should be re-started once the INR is in the therapeutic range if it is still indicated.
- » In patients with superwarfarin toxicity, treatment with vitamin K<sub>1</sub> may need to be prolonged for several months as superwarfarins are very long acting. Discuss with the Poisons Information Centre or haematologist for advice on dosing and duration of treatment.

LoE:IVb<sup>xxii</sup>



## 19.20 CARBON MONOXIDE POISONING

T58 + (X47.99/X67.99/Y17.99)

### DESCRIPTION

Poisoning caused by accidental or intentional exposure to fires in poorly ventilated areas, combustion engines, faulty stoves, and faulty heating systems.

Patients present with:

- » dizziness
- » impaired level of consciousness
- » headache
- » tachycardia
- » seizures and other CNS symptoms
- » chest pain
- » nausea and vomiting
- » retinal haemorrhages
- » metabolic acidosis (severe)
- » respiratory alkalosis (mild)
- » high arterial carboxyhaemoglobin levels

**Note:** There may be a normal arterial PaO<sub>2</sub>, but low oxygen saturation on pulse oximetry. Neither are useful in assessing severity of carbon monoxide poisoning. Ideally, a blood gas sample should be sent for co-oximetry to specifically detect carboxyhaemoglobin levels.

### GENERAL MEASURES

- » Remove patient from toxic environment.
- » Ventilation may be needed in deeply comatosed patients.
- » Monitor ECG and neurological status.

### MEDICINE TREATMENT

- Oxygen, 100%, via positive pressure facemask.

For seizures: R56.8 + (T58 + X47.99/X67.99/Y17.99)

Treat with benzodiazepines - see section: 14.4.1 Status epilepticus.

**Note:** Phenytoin should be avoided (due to potential cardiotoxicity).

LoE:IVb<sup>xxiii</sup>

### Metabolic acidosis:

Metabolic acidosis shifts the oxygen-dissociation curve to the right and therefore aids in maintaining tissue oxygenation despite reduced haemoglobin carrying capacity. Metabolic acidosis should only be treated if profound and persistent, following standard treatment protocols.

Patients should be followed up after discharge for the persistence of neurocognitive symptoms.

## 19.21 HEAVY METAL POISONING

T56.0/T56.1/T56.4/T56.8/T57.0

### DESCRIPTION

This includes mercury, arsenic, gold, copper, lead poisoning, thallium etc. Frequent/occupational inhalation of metal fumes and particles can cause metal fume fever, a flu-like syndrome with fever, malaise, bronchospasm, and bi-weekly variations in severity that may be mildest on the weekend and most severe on Monday or Tuesday after returning to work. This may be confused with an acute viral illness with fever, cough, sweating, myalgia, headache etc. The course of the illness is usually benign.

The management of heavy metal toxicity depends on the specific metal, route of exposure and length of time between exposure and clinical presentation of symptoms. Discuss all potential patients with the Poisons Information Helpline for further investigation, treatment options and possible referral.

LoE:IVb<sup>xxiv</sup>

Metal	Signs and symptoms
Copper salts	GIT irritation, hepatotoxicity, and haemolysis.
Arsenic	Impairs cellular respiration, resulting in multi-organ dysfunction.
Mercury	Clinical effects depend on the route of exposure and type of mercury (inorganic versus organic).
Lead	Chronic toxicity more common. Affects nervous, gastrointestinal, renal, and haematopoietic systems.
Gold	Deposition of immune complexes in kidneys and skin; mucus membrane inflammation
Thallium	Alopecia and painful ascending peripheral neuropathy.

**Table 19.6:** Clinical features of heavy metal poisoning

LoE:IVb<sup>xxv</sup>

## 19.22 POISONING WITH SUBSTANCES THAT CAUSE METHAEMOGLOBINAEMIA

D74.9 + (T41.3/T41.4/T46.3 + X44.99/X64.99/Y14.99)

### DESCRIPTION

- » Substances causing methaemoglobinaemia include nitrites, nitroglycerine, dapson, mothballs (naphthalene), local anaesthetics, phenazopyridine, chlorates, and anilines.
- » Nitrites are used to cure meat in the formal and informal butchery sector.
- » Patients present with:
  - Deep cyanosis with only mildly reduced oxygen saturation
  - CNS depression, and
  - arrhythmias.

**Note:** Methaemoglobinaemia causes patients to appear cyanosed with falsely high conventional pulse oximetry readings and normal PaO<sub>2</sub>. Blood gas analysis using co-oximetry is required to specifically measure methaemoglobin levels.

### **MEDICINE TREATMENT**

- Oxygen via facemask.

In symptomatic cases or patients with high methaemoglobin values > 30%:

- Methylene blue (methylthionine chloride) 1% dilute solution, slow IV infusion, 1–2 mg/kg administered over 5 minutes.
  - Repeat in 1 hour and, if necessary, 4 hourly up to a total dose of 7 mg/kg.
  - Side effects include precordial pain, restlessness, and dyspnoea.
  - After administration of methylene blue, oxygen saturation may drop initially.

In life-threatening cases not responding to methylene blue, or if methylene blue is not available, exchange transfusion may be considered. Refer to the Poisons Information Helpline for advice on treatment and possible alternatives to methylene blue.

## References:

- <sup>i</sup> Amoxicillin/clavulanic acid, oral: Blaylock RS. Antibiotic use and infection in snakebite victims. *S Afr Med J*. 1999 Aug;89(8):874-6. <http://www.ncbi.nlm.nih.gov/pubmed/10488365>
- <sup>ii</sup> NSAID caution: World Health Organisation: Guidelines for the prevention and clinical management of snakebite in Africa. <https://www.who.int/health-topics/snakebite#tab=overview>
- <sup>iii</sup> Polyvalent antivenom: Wood D, Webb C, DeMeyer J. Severe snakebites in northern KwaZulu-Natal: treatment modalities and outcomes. *S Afr Med J*. 2009 Nov;99(11):814-8. <http://www.ncbi.nlm.nih.gov/pubmed/20218483>
- <sup>iv</sup> Polyvalent antivenom: Müller GJ, Modler H, Wium CA, Veale DJH, Marks CJ. Snake bite in southern Africa: diagnosis and management. *CME Oct 2012*; 30(10):362-82. <http://www.cmei.org.za/index.php/cmei/article/view/2546/2581>
- SAMF 14th edition, page 653
- <sup>v</sup> Antivenom (period to administer): Müller GJ, Modler H, Wium CA, Veale DJH, Marks CJ. Snake bite in southern Africa: diagnosis and management. *CME Oct 2012*; 30(10):362-82. <http://www.cmei.org.za/index.php/cmei/article/view/2546/2581>
- <sup>v</sup> Polyvalent snake antivenom (indications): Wood D, Sartorius B, Hift R. Snakebite in NE South Africa: clinical characteristics and risks for severity. *S Afr Fam Prac* 2016; 58(2):62-67. <https://www.tandfonline.com/doi/full/10.1080/20786190.2015.1120934>
- <sup>v</sup> Polyvalent snake antivenom (indications): Wood, Sartorius, Hift. Classifying snakebite in South Africa: validating a scoring system. *S Afr Med J* 2017;107(1):46-51. <https://www.ncbi.nlm.nih.gov/pubmed/28112091>
- Hardcastle TC et al (progressive cytotoxic envenomation) . Approach to the diagnosis and management of snakebite envenomation in South Africa in humans: The hospital phase – emergency unit general principles. *SAMJ* June 2023 Vol 113, No6.
- <sup>vi</sup> Adrenaline (epinephrine), SC: Nuchpraryoon I, Garner P. Interventions for preventing reactions to snake antivenom. *Cochrane Database Syst Rev*. 2000;(2):CD002153. Review. <http://www.ncbi.nlm.nih.gov/pubmed/21572992>
- Adrenaline (epinephrine), SC: de Silva HA, Pathmeswaran A, Ranasinha CD, Jayamanne S, Samarakoon SB, Hittharage A, Kalupahana R, Ratnatilaka GA, Uluwathage W, Aronson JK, Armitage JM, Lalloo DG, de Silva HJ. Low-dose adrenaline, promethazine, and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: a randomised, double-blind, placebo-controlled trial. *PLoS Med*. 2011 May;8(5):e1000435. <http://www.ncbi.nlm.nih.gov/pubmed/21572992>
- <sup>vii</sup> Polyvalent antivenom (neurotoxic, cytotoxic or unidentified snakebites): Müller GJ, Modler H, Wium CA, Veale DJH, Marks CJ. Snake bite in southern Africa: diagnosis and management. *CME Oct 2012*; 30(10):362-82. <http://www.cmei.org.za/index.php/cmei/article/view/2546/2581>
- <sup>viii</sup> Polyvalent antivenom: South African Medicines Formulary. 14th Edition. Division of Clinical Pharmacology. University of Cape Town, 2022.
- <sup>viii</sup> Polyvalent antivenom (cytotoxic Mozambique spitting cobra bite): World Health Organisation: Guidelines for the prevention and clinical management of snakebite in Africa. <https://www.who.int/health-topics/snakebite#tab=overview>
- <sup>ix</sup> Boomslang monovalent antivenom (neurotoxic, cytotoxic or unidentified snakebites): Müller GJ, Modler H, Wium CA, Veale DJH, Marks CJ. Snake bite in southern Africa: diagnosis and management. *CME Oct 2012*; 30(10):362-82. <http://www.cmei.org.za/index.php/cmei/article/view/2546/2581>
- <sup>x</sup> Boomslang monovalent antivenom: Guidelines for the prevention and clinical management of snakebite in Africa. <https://www.who.int/health-topics/snakebite#tab=overview>
- <sup>xi</sup> Local anaesthetic ophthalmic drops (therapeutic group): Lawrenson JG, Edgar DF, Tanna GK, Gudgeon AC. Comparison of the tolerability and efficacy of unit-dose, preservative-free topical ocular anaesthetics. *Ophthalmic Physiol Opt*. 1998 Sep;18(5):393-400. <https://pubmed.ncbi.nlm.nih.gov/10023471/>
- <sup>xii</sup> Polyvalent antivenom (snake venom in the eye): Müller GJ, Modler H, Wium CA, Veale DJH, Marks CJ. Snake bite in southern Africa: diagnosis and management. *CME Oct 2012*; 30(10):362-82. <http://www.cmei.org.za/index.php/cmei/article/view/2546/2581>
- <sup>xiii</sup> Paracetamol, oral: Müller GJ, Modler H, Wium CA, Veale DJH, Marks CJ. Scorpion sting in southern Africa: diagnosis and management. *CME Oct 2012*; 30(10):356-61. <http://www.cmei.org.za/index.php/cmei/article/view/2545/2580>
- <sup>xiii</sup> Lidocaine. 1-2%, infiltration: Aksef G, Güler S, Doğan N, Corbacioğlu S. A randomized trial comparing intravenous paracetamol, topical lidocaine, and ice application for treatment of pain associated with scorpion stings. *Hum Exp Toxicol*. 2014 Oct 10. pii: 0960327114551394. [Epub ahead of print] <http://www.ncbi.nlm.nih.gov/pubmed/25304965>
- <sup>xiii</sup> Lidocaine. 1-2%, infiltration: Chippaux JP. Emerging options for the management of scorpion stings. *Drug Des Devel Ther*. 2012;6:165-73. <http://www.ncbi.nlm.nih.gov/pubmed/22826633>
- <sup>xiv</sup> Opiates (caution): Müller GJ, Modler H, Wium CA, Veale DJH, Marks CJ. Scorpion sting in southern Africa: diagnosis and management. *CME Oct 2012*; 30(10):356-61. <http://www.cmei.org.za/index.php/cmei/article/view/2545/2580>
- <sup>xv</sup> Scorpion sting: Muller, G J et al. Scorpion sting in southern Africa: diagnosis and management. *Continuing Medical Education*, [S.l.], v. 30, n. 10, p. 356-361, sep. 2012. ISSN 2078-5143. Available at: <<http://www.cmei.org.za/index.php/cmei/article/view/2545/2580>>. Date accessed: 18 Apr. 2023.
- <sup>xvi</sup> Calcium gluconate 10%, bolus IV: South African Medicines Formulary. 14th Edition. Division of Clinical Pharmacology. University of Cape Town, 2022.
- Package Insert: Calcium Gluconate Injection Fresenius solution for injection. Fresenius Kabi Manufacturing SA (Pty) Ltd. Last revised 7 February 2023.
- Shann F. Drug doses: 17<sup>th</sup> Edition. 2017.

- <sup>xvii</sup> Spider antivenom: Muller GJ, Wium CA, Marks CJ, du Plessis CE, Veale DJH. Spider bite in southern Africa: diagnosis and management. *CME* October 2012;30(10): 382-91. <http://www.cmej.org.za/index.php/cmej/article/view/2547/2582>
- <sup>xviii</sup> Calcium gluconate 10%, bolus IV: South African Medicines Formulary. 14th Edition. Division of Clinical Pharmacology. University of Cape Town, 2022.  
Package Insert: Calcium Gluconate Injection Fresenius solution for injection. Fresenius Kabi Manufacturing SA (Pty) Ltd. Last revised 7 February 2023.  
Shann F. Drug doses: 17<sup>th</sup> Edition. 2017.
- <sup>xix</sup> Gastric lavage: Benson BE, Hoppu K, Troutman WG, Bedry R, Erdman A, Höjer J, Mégarbane B, Thanacoody R, Caravati EM; American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Position paper update: gastric lavage for gastrointestinal decontamination. *Clin Toxicol (Phila)*. 2013 Mar;51(3):140-6. <https://www.ncbi.nlm.nih.gov/pubmed/23418938>
- <sup>xx</sup> Activated charcoal (multi-dose): Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. *J Toxicol Clin Toxicol*. 1999;37(6):731-51. <http://www.ncbi.nlm.nih.gov/pubmed/10584586>
- <sup>xxi</sup> Activated charcoal (single dose): National Department of Health: Affordable Medicines, EDP-Adult Hospital level. Medicine Review: Single dose activated charcoal for poisonings, May 2019. <http://www.health.gov.za/>
- Activated charcoal (single dose): Chyka PA, Seger D; American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Position statement: single-dose activated charcoal. *J Toxicol Clin Toxicol* 1997;35(7):721-41. <https://www.ncbi.nlm.nih.gov/pubmed/15822758>
- Activated charcoal (single dose): Rosenberg J, Benowitz NL, Pond S. Pharmacokinetics of drug overdose. *Clin Pharmacokinet* 1981; 6:161– 192. <https://www.ncbi.nlm.nih.gov/pubmed/7016383>
- Activated charcoal (single dose): Yeates PJA, Thomas SHL. Effectiveness of delayed activated charcoal administration in simulated paracetamol (acetaminophen) overdose. *Br J Clin Pharmacol* 2000; 49:11–14. <https://www.ncbi.nlm.nih.gov/pubmed/7016383>
- Activated charcoal (single dose): Laine K, Kivisto<sup>™</sup> KT, Pelttari S, Neuvonen PJ. The effect of activated charcoal on the absorption of fluoxetine, with special reference to delayed charcoal administration. *Pharmacol Toxicol* 1996; 79:270– 273. <https://www.ncbi.nlm.nih.gov/pubmed/8936562>
- Activated charcoal (single dose): Laine K, Kivisto<sup>™</sup> KT, Neuvonen PJ. Effect of delayed administration of activated charcoal on the absorption of conventional and slow-release verapamil. *J Toxicol Clin Toxicol* 1997; 35:263–268. <https://www.ncbi.nlm.nih.gov/pubmed/9140320>
- Activated charcoal (single dose): Laine K, Kivisto<sup>™</sup> KT, Ojala-Karlsson P, Neuvonen PJ. Effect of activated charcoal on the pharmacokinetics of pholcodine, with special reference to delayed charcoal ingestion. *Ther Drug Monit* 1997; 19:46– 50. <https://www.ncbi.nlm.nih.gov/pubmed/9029746>
- Activated charcoal (single dose): Green R, Grierson R, Sitar DS, Tenenbein M. How long after drug ingestion is activated charcoal still effective? *J Toxicol Clin Toxicol* 2001; 39:601– 605. <https://www.ncbi.nlm.nih.gov/pubmed/11762668>
- <sup>xxii</sup> Whole bowel irrigation (with polyethylene glycol): Thanacoody R, Caravati EM, Troutman B, Hojer J, Benson B, Hoppu K et al. Position paper update: whole bowel irrigation for gastrointestinal decontamination of overdose patients. *Clin Toxicol (Phila)* 2015;53:5-12. <https://www.ncbi.nlm.nih.gov/pubmed/25511637>
- <sup>xxiii</sup> Paracetamol overdosing – repeated subtherapeutic ingestion: Chiew AL, Reith D, Pomerleau A, Wong A, Isoardi KZ, Soderstrom J, Buckley NA. Updated guidelines for the management of paracetamol poisoning in Australia and New Zealand. *Med J Aust*. 2020 Mar;212(4):175-183. <https://pubmed.ncbi.nlm.nih.gov/31786822/>
- <sup>xxiv</sup> Paracetamol nomogram: Chiew AL, Reith D, Pomerleau A, Wong A, Isoardi KZ, Soderstrom J, Buckley NA. Updated guidelines for the management of paracetamol poisoning in Australia and New Zealand. *Med J Aust*. 2020 Mar;212(4):175-183. <https://pubmed.ncbi.nlm.nih.gov/31786822/>
- Paracetamol nomogram: Daly FF, Fountain JS, Murray L, Graudins A, Buckley NA; Panel of Australian and New Zealand clinical toxicologists. Guidelines for the management of paracetamol poisoning in Australia and New Zealand – explanation and elaboration. A consensus statement from clinical toxicologists consulting to the Australasian poisons information centres. *Med J Aust*. 2008 Mar 3;188(5):296-301. <http://www.ncbi.nlm.nih.gov/pubmed/18312195>
- <sup>xxv</sup> N-Acetylcysteine, IV (dosing regimen): Chiew AL, Reith D, Pomerleau A, Wong A, Isoardi KZ, Soderstrom J, Buckley NA. Updated guidelines for the management of paracetamol poisoning in Australia and New Zealand. *Med J Aust*. 2020 Mar;212(4):175-183. <https://pubmed.ncbi.nlm.nih.gov/31786822/>
- N-Acetylcysteine, IV (dosing regimen): Wong A, Graudins A. Simplification of the standard three-bag intravenous acetylcysteine regimen for paracetamol poisoning results in a lower incidence of adverse drug reactions. *Clin Toxicol (Phila)*. 2016;54(2):115-9. <https://www.ncbi.nlm.nih.gov/pubmed/26594846>
- <sup>xxvi</sup> N-acetylcysteine, oral (dosing for paracetamol poisoning): Yarema MC, Johnson DW, Berlin RJ, Sivilotti ML, Nettel-Aguirre A, Brant RF, et al. Comparison of the 20-hour intravenous and 72-hour oral acetylcysteine protocols for the treatment of acute acetaminophen poisoning. *Ann Emerg Med*. 2009 Oct;54(4):606-14. <https://www.ncbi.nlm.nih.gov/pubmed/19556028>
- N-acetylcysteine, oral (dosing for paracetamol poisoning): Williamson K, Wahl MS, Mycyk MB. Direct comparison of 20-hour IV, 36-hour oral, and 72-hour oral acetylcysteine for treatment of acute acetaminophen poisoning. *Am J Ther*. 2013 Jan;20(1):37-40. <https://www.ncbi.nlm.nih.gov/pubmed/23299230>
- N-acetylcysteine, oral (dosing for paracetamol poisoning): Rumack and Bateman. Acetaminophen and acetylcysteine dose and duration: past, present and future. *Clin Toxicol (Phila)* 2012;50(2):91-98. <https://www.ncbi.nlm.nih.gov/pubmed/22320209>

- <sup>xxxvii</sup> N-acetylcysteine, oral (adverse effects): South African Medicines Formulary. 14th Edition. Division of Clinical Pharmacology. University of Cape Town, 2022.
- <sup>xxxviii</sup> Activated charcoal:Bradberry SM, Vale JA. Multiple-dose activated charcoal: a review of relevant clinical studies. *J ToxicolClinToxicol*. 1995;33(5):407-16. Review. <http://www.ncbi.nlm.nih.gov/pubmed/7650765>
- Whole bowel irrigation:Mayer AL, Sitar DS, Tenenbein M. Multiple-dose charcoal and whole-bowel irrigation do not increase clearance of absorbed salicylate. *Arch Intern Med*. 1992 Feb;152(2):393-6. <http://www.ncbi.nlm.nih.gov/pubmed/1739372>
- <sup>xxxix</sup> Activated charcoal:Bradberry SM, Vale JA. Multiple-dose activated charcoal: a review of relevant clinical studies. *J ToxicolClinToxicol*. 1995;33(5):407-16. Review.<http://www.ncbi.nlm.nih.gov/pubmed/7650765>
- Whole bowel irrigation:Mayer AL, Sitar DS, Tenenbein M. Multiple-dose charcoal and whole-bowel irrigation do not increase clearance of absorbed salicylate. *Arch Intern Med*. 1992 Feb;152(2):393-6. <http://www.ncbi.nlm.nih.gov/pubmed/1739372>
- <sup>xl</sup> Dextrose (salicylate poisoning): Kuzak N, Brubacher JR, Kennedy JR. Reversal of salicylate-induced euglycemic delirium with dextrose. *Clin Toxicol (Phila)*. 2007 Jun-Aug;45(5):526-9. <https://pubmed.ncbi.nlm.nih.gov/17503260/>
- <sup>xli</sup> Sodium bicarbonate (salicylate poisoning): Prescott LF, Balali-Mood M, Critchley JA, Johnstone AF, Proudfoot AT. Diuresis or urinary alkalinisation for salicylate poisoning? *Br Med J (Clin Res Ed)*. 1982 Nov 13;285(6352):1383-6. <https://pubmed.ncbi.nlm.nih.gov/6291695/>
- <sup>xlii</sup> Haemodialysis (salicylate poisoning): McCabe DJ, Lu JJ. The association of hemodialysis and survival in intubated salicylate-poisoned patients. *Am J Emerg Med*. 2017 Apr 10. pii: S0735-6757(17)30280-2. <https://www.ncbi.nlm.nih.gov/pubmed/28438446>
- Haemodialysis (salicylate poisoning): Juurlink DN, Gosselin S, Kielstein JT, Ghannoum M, Lavergne V, Nolin TD, Hoffman RS; EXTRIP Workgroup. Extracorporeal Treatment for Salicylate Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup. *Ann Emerg Med*. 2015 Aug;66(2):165-81. <https://pubmed.ncbi.nlm.nih.gov/25986310/>
- <sup>xliiii</sup> Naloxone: South African Medicines Formulary. 14th Edition. Division of Clinical Pharmacology. University of Cape Town, 2022.
- Naloxone: FDA approved package insert – Hospira Inc.: Naloxone Hydrochloride, 2015. <http://medlibrary.org/lib/rx/meds/naloxone-hydrochloride-8/>
- <sup>xliiii</sup> TCAs - toxicity: David M. Taylor, Thomas R. E. Barnes, Allan H. Young. The Maudsley prescribing guidelines in psychiatry.13th edition. Hoboken, NJ : Wiley, 2019. (page 770).
- <sup>xliiii</sup> Sodium bicarbonate, IV (tricyclic antidepressant poisoning): Bruccoleri RE, Burns MM. A Literature Review of the Use of Sodium Bicarbonate for the Treatment of QRS Widening. *J Med Toxicol*. 2016 Mar;12(1):121-9. <https://www.ncbi.nlm.nih.gov/pubmed/26159649>
- <sup>xliiii</sup> Phenytoin (tricyclic antidepressant poisoning): South African Medicines Formulary. 14th Edition. Division of Clinical Pharmacology. University of Cape Town, 2022.
- <sup>xliiii</sup> Flumazenil (tricyclic antidepressant poisoning): Penninga EI, Graudal N, Ladekari MB, Jürgens G. Adverse Events Associated with Flumazenil Treatment for the Management of Suspected Benzodiazepine Intoxication - A Systematic Review with Meta-Analyses of Randomised Trials. *Basic ClinPharmacolToxicol*. 2016 Jan;118(1):37-44. <http://www.ncbi.nlm.nih.gov/pubmed/26096314>
- <sup>xliiii</sup> Desferrioxamine, IV: Tenenbein M. Benefits of parenteral deferoxamine for acute iron poisoning. *J ToxicolClinToxicol*. 1996;34(5):485-9. <http://www.ncbi.nlm.nih.gov/pubmed/8800185>
- Desferrioxamine, IV: Tenenbein M, Kowalski S, Sienko A, Bowden DH, Adamson IY. Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning. *Lancet*. 1992 Mar 21;339(8795):699-701. <http://www.ncbi.nlm.nih.gov/pubmed/1347583>
- Desferrioxamine, IV: South African Medicines Formulary. 14th Edition. Division of Clinical Pharmacology. University of Cape Town, 2022.
- <sup>xliiii</sup> Deferoxamine (IV admin) Drug Monograph. Deferoxamine. Clinical Key accessed 3 February 2023. <https://www.clinicalkey.com/#!/content/6-s2-0-170?scrollTo=%23top>
- Package Insert. Desferal. Novartis 10 Aug 2006.
- <sup>xliv</sup> Desferrioxamine, IV (pregnancy): Piccioni MG, Capone C, Vena F, Del Negro V, Schiavi MC, D'Ambrosio V, Giacotti A, Smacchia MP, Brunelli R. Use of deferoxamine (DFO) in transfusion-dependent  $\beta$ -thalassaemia during pregnancy: A retrospective study. *Taiwan J Obstet Gynecol*. 2020 Jan;59(1):120-122. <https://pubmed.ncbi.nlm.nih.gov/32039778/>
- <sup>xlv</sup> Activated charcoal (multi-dose): Ghannoum M, Wiegand TJ, Liu KD, Calello DP, Godin M, Lavergne V, Gosselin S, Nolin TD, Hoffman RS; EXTRIP workgroup. Extracorporeal treatment for theophylline poisoning: systematic review and recommendations from the EXTRIP workgroup. *Clin Toxicol (Phila)*. 2015 May;53(4):215-29. <https://www.ncbi.nlm.nih.gov/pubmed/25715736>
- <sup>xlvi</sup> Potassium chloride, IV: Ghannoum M, Wiegand TJ, Liu KD, Calello DP, Godin M, Lavergne V, Gosselin S, Nolin TD, Hoffman RS; EXTRIP workgroup. Extracorporeal treatment for theophylline poisoning: systematic review and recommendations from the EXTRIP workgroup. *Clin Toxicol (Phila)*. 2015 May;53(4):215-29. <https://www.ncbi.nlm.nih.gov/pubmed/25715736>
- <sup>xlvii</sup> Phenytoin (seizures secondary to poisonings): South African Medicines Formulary. 14th Edition. Division of Clinical Pharmacology. University of Cape Town, 2022.
- <sup>xlviii</sup> Haemodialysis: Activated charcoal (multi-dose): Ghannoum M, Wiegand TJ, Liu KD, Calello DP, Godin M, Lavergne V, Gosselin S, Nolin TD, Hoffman RS; EXTRIP workgroup. Extracorporeal treatment for theophylline poisoning: systematic review and recommendations from the EXTRIP workgroup. *Clin Toxicol (Phila)*. 2015 May;53(4):215-29. <https://www.ncbi.nlm.nih.gov/pubmed/25715736>
- <sup>xlix</sup> Flumazenil: Penninga EI, Graudal N, Ladekari MB, Jürgens G. Adverse Events Associated with Flumazenil Treatment for the Management of Suspected Benzodiazepine Intoxication - A Systematic Review with Meta-

- Analyses of Randomised Trials. *Basic Clin Pharmacol Toxicol.* 2016 Jan;118(1):37-44. <https://www.ncbi.nlm.nih.gov/pubmed/26096314>
- <sup>xv</sup>Whole bowel irrigation (with polyethylene glycol): Thanacoody R, Caravati EM, Troutman B, Hojer J, Benson B, Hoppu K et al. Position paper update: whole bowel irrigation for gastrointestinal decontamination of overdose patients. *Clin Toxicol (Phila)* 2015;53:5-12. <https://www.ncbi.nlm.nih.gov/pubmed/25511637>
- <sup>xvii</sup> Phenytoin (seizures secondary to poisonings): South African Medicines Formulary. 12th Edition. Division of Clinical Pharmacology. University of Cape Town, 2022.
- <sup>xviii</sup> Haemodialysis (early referral): Decker BS, Goldfarb DS, Dargan PI, Friesen M, Gosselin S, Hoffman RS, Lavergne V, Nolin TD, Ghannoum M; EXTRIP Workgroup. Extracorporeal Treatment for Lithium Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. *Clin J Am Soc Nephrol.* 2015 May 7;10(5):875-87. <https://www.ncbi.nlm.nih.gov/pubmed/25583292>
- <sup>xix</sup>Pyridoxine, oral: Lheureux P, Penaloza A, Gris M. Pyridoxine in clinical toxicology: a review. *Eur J Emerg Med.* 2005 Apr;12(2):78-85. <http://www.ncbi.nlm.nih.gov/pubmed/15756083>
- Pyridoxine, oral: Dilrukshi M, Ratnayake C, Gnanathasan C. Oral pyridoxine can substitute for intravenous pyridoxine in managing patients with severe poisoning with isoniazid and rifampicin fixed dose combination tablets: a case report. *BMC Res Notes* 2017;10:370. <https://www.ncbi.nlm.nih.gov/pubmed/28789699>
- <sup>i</sup> Benzodiazepines (seizures in INH toxicity): Hoffman RS, Howlands MA, Lewin NA, Nelson LS, Goldfrank LR. *Goldfrank's Toxicologic Emergencies.* 10<sup>th</sup> ed. China: McGraw-Hill Education; 2015.
- <sup>ii</sup> Phenytoin (avoid in isoniazid poisoning): Hoffman RS, Howlands MA, Lewin NA, Nelson LS, Goldfrank LR. *Goldfrank's Toxicologic Emergencies.* 10<sup>th</sup> ed. China: McGraw-Hill Education; 2015.
- <sup>iii</sup> Calcium channel blocker poisonings and beta-blocker poisonings (similar management): Graudins A, Lee HM, Druda D. Calcium channel antagonist and beta-blocker overdose: antidotes and adjunct therapies. *Br J Clin Pharmacol.* 2016 Mar;81(3):453-61. <https://www.ncbi.nlm.nih.gov/pubmed/26344579>
- <sup>iiii</sup> Gut decontamination (Gastric lavage, activated charcoal administration or whole bowel irrigation): St-Onge M, Anseeuw K, Cantrell FL, Gilchrist IC, Hantson P, Bailey B, Lavergne V, Gosselin S, Kerns W 2nd, Laliberté M, Lavonias EJ, Juurlink DN, Muscedere J, Yang CC, Sinuff T, Rieder M, Mégarbane B. Experts Consensus Recommendations for the Management of Calcium Channel Blocker Poisoning in Adults. *Crit Care Med.* 2017 Mar;45(3):e306-e315. <https://www.ncbi.nlm.nih.gov/pubmed/27749343>
- <sup>iv</sup> Atropine, IV: Proano L, Chiang WK, Wang RY. Calcium channel blocker overdose. *Am J Emerg Med.* 1995 Jul;13(4):444-50. <http://www.ncbi.nlm.nih.gov/pubmed/7605536>
- <sup>lv</sup> Sodium chloride, 0.9%, IV: Proano L, Chiang WK, Wang RY. Calcium channel blocker overdose. *Am J Emerg Med.* 1995 Jul;13(4):444-50. <http://www.ncbi.nlm.nih.gov/pubmed/7605536>
- <sup>lvii</sup> Calcium gluconate 10%, IV (calcium channel blocker toxicity): Proano L, Chiang WK, Wang RY. Calcium channel blocker overdose. *Am J Emerg Med.* 1995 Jul;13(4):444-50. <http://www.ncbi.nlm.nih.gov/pubmed/7605536>
- Calcium gluconate 10%, IV (calcium channel blocker toxicity): Graudins A, Lee HM, Druda D. Calcium channel antagonist and beta-blocker overdose: antidotes and adjunct therapies. *Br J Clin Pharmacol.* 2016 Mar;81(3):453-61. <https://www.ncbi.nlm.nih.gov/pubmed/26344579>
- <sup>lviii</sup> Phenytoin (seizures secondary to poisonings): South African Medicines Formulary. 14th Edition. Division of Clinical Pharmacology. University of Cape Town, 2022.
- <sup>lix</sup> Phenytoin (seizures secondary to poisonings): South African Medicines Formulary. 14th Edition. Division of Clinical Pharmacology. University of Cape Town, 2022.
- <sup>lx</sup> Endoscopic evaluation (within 24-48 hours): Millar AJ, Cox SG. Caustic injury of the oesophagus. *Pediatr Surg Int.* 2015 Feb;31(2):111-21. <https://www.ncbi.nlm.nih.gov/pubmed/25432099>
- <sup>lxi</sup> Ethanol (indications for antidote): McMartin K, Jacobsen D, Hovda KE. Antidotes for poisoning by alcohols that form toxic metabolites. *Br J Clin Pharmacol.* 2016 Mar;81(3):505-15. <https://www.ncbi.nlm.nih.gov/pubmed/26551875>
- <sup>lxii</sup> Ethanol (dosing of antidote): McMartin K, Jacobsen D, Hovda KE. Antidotes for poisoning by alcohols that form toxic metabolites. *Br J Clin Pharmacol.* 2016 Mar;81(3):505-15. <https://www.ncbi.nlm.nih.gov/pubmed/26551875>
- <sup>lxiii</sup> Co-factor therapy (ethylene glycol poisoning): Frommer JP, Ayus JC. Acute ethylene glycol intoxication. *Am J Nephrol.* 1982;2(1):1-5. <https://pubmed.ncbi.nlm.nih.gov/7180899/>
- <sup>lxiv</sup> Metabolic acidosis cautions: McMartin K, Jacobsen D, Hovda KE. Antidotes for poisoning by alcohols that form toxic metabolites. *Br J Clin Pharmacol.* 2016 Mar;81(3):505-15. <https://www.ncbi.nlm.nih.gov/pubmed/26551875>
- <sup>lxv</sup> Ethanol antidote and haemodialysis (methanol poisoning): Jacobsen D, McMartin KE. Antidotes for methanol and ethylene glycol poisoning. *J Toxicol Clin Toxicol.* 1997;35(2):127-43. <https://www.ncbi.nlm.nih.gov/pubmed/9120880>
- Ethanol antidote and haemodialysis (methanol poisoning): Roberts DM, Yates C, Megarbane B, Winchester JF, Maclaren R, Gosselin S, Nolin TD, Lavergne V, Hoffman RS, Ghannoum M; EXTRIP Work Group. Recommendations for the role of extracorporeal treatments in the management of acute methanol poisoning: a systematic review and consensus statement. *Crit Care Med.* 2015 Feb;43(2):461-72. <https://www.ncbi.nlm.nih.gov/pubmed/25493973>
- <sup>lxvi</sup> Phenytoin (seizures secondary to poisonings): South African Medicines Formulary. 14th Edition. Division of Clinical Pharmacology. University of Cape Town, 2022.
- <sup>lxvii</sup> Intermediate syndrome in organophosphate poisoning: Eddleston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus pesticide poisoning. *Lancet.* 2008 Feb 16;371(9612):597-607. <https://www.ncbi.nlm.nih.gov/pubmed/17706760>
- <sup>lxviii</sup> Organophosphate poisoning – healthcare worker protection: Little M, Murray L; Poison Information Centres of New South Wales, Western Australia, Queensland, New Zealand, and the Australian Capital Territory. Consensus statement: risk of nosocomial organophosphate poisoning in emergency departments. *Emerg Med Australas.* 2004 Oct-Dec;16(5-6):456-8. <https://www.ncbi.nlm.nih.gov/pubmed/15537409>
- Organophosphate poisoning – healthcare worker protection: Centers for Disease Control and Prevention (CDC). Nosocomial poisoning associated with emergency department treatment of organophosphate toxicity--Georgia, 2000. *MMWR Morb Mortal Wkly Rep.* 2001 Jan 5;49(51-52):1156-8. <https://www.ncbi.nlm.nih.gov/pubmed/11198947>

- Organophosphate poisoning – healthcare worker protection: Stacey R, Morley D, Payne S. Secondary contamination in organophosphate poisoning: analysis of an incident. QJM. 2004 Feb;97(2):75-80. <https://www.ncbi.nlm.nih.gov/pubmed/14747621>
- <sup>ixviii</sup> Atropine, IV (bolus dose): Abedin MJ, Sayeed AA, Basher A, Maude RJ, Hoque G, Faiz MA. Open-label randomized clinical trial of atropine bolus injection versus incremental boluses plus infusion for organophosphate poisoning in Bangladesh. J Med Toxicol. 2012 Jun;8(2):108-17. <http://www.ncbi.nlm.nih.gov/pubmed/22351300>
- <sup>ixx</sup> Atropine, IV (protocol): Eddleston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus pesticide poisoning. Lancet. 2008 Feb 16;371(9612):597-607. <https://www.ncbi.nlm.nih.gov/pubmed/17706760>
- Atropine, IV (protocol): Eddleston M, Dawson A, Karaliedde L, Dissanayake W, Hittarage A, Azher S, Buckley NA. Early management after self-poisoning with an organophosphorus carbamate pesticide - a treatment protocol for junior doctors. Crit Care. 2004 Dec;8(6):R391-7. <https://www.ncbi.nlm.nih.gov/pubmed/15566582>
- <sup>ixxi</sup> Diazepam, IV (seizures in organophosphate poisoning): Eddleston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus pesticide poisoning. Lancet. 2008 Feb 16;371(9612):597-607. <https://www.ncbi.nlm.nih.gov/pubmed/17706760>
- <sup>ixxii</sup> Freshfrozen plasma: Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun;133(6 Suppl):160S-198S. <http://www.ncbi.nlm.nih.gov/pubmed/18574265>
- <sup>ixxiii</sup> Watt BE et al. Anticoagulant rodenticides. Toxicol Rev 2005;24(4): 259-269
- Toxinz and Toxbase – June 2022 printouts  
Oxford Desk Reference Toxicology 2014 p311-312.  
Goldfrank Toxicologic Emergencies 10th ed. P820 and 836-838.
- <sup>ixxiv</sup> Phenytoin (seizures secondary to poisonings): South African Medicines Formulary. 14th Edition. Division of Clinical Pharmacology. University of Cape Town, 2022.
- <sup>ixxv</sup> Heavy metal poisoning (flu-like syndrome): Brenner BE, Keyes D. Metal Fume Fever. [Updated 2023 Aug 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK583199/>.
- Nelson LS, Odujebi OA. Simple Asphyxiants and Pulmonary Irritants. In: Nelson LS, Howland M, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS. eds. Goldfrank's Toxicologic Emergencies, 11e. McGraw-Hill Education; 2019. Accessed April 16, 2024. <https://accesspharmacy.mhmedical.com/content.aspx?bookid=2569&sectionid=210264279>  
<https://www.msdmanuals.com/professional/special-subjects/occupational-and-environmental-medicine/metal-fume-fever-and-polymer-fume-fever?query=metal%20fume%20fever%20and%20polymer%20fume%20fever>
- <sup>ixxvi</sup> Heavy metal poisoning (signs and symptoms): AfriTox 2019. [Accessed September 2019]. [www.afritox.co.za](http://www.afritox.co.za)



**SOUTH AFRICAN ADULT HOSPITAL LEVEL ESSENTIAL MEDICINES LIST  
CHAPTER 19: POISONINGS**

**NEMLC RECOMMENDATIONS FOR MEDICINE AMENDMENTS (2020-4 REVIEW CYCLE)**

Medicine amendment recommendations, with supporting evidence and rationale are listed below. Kindly review the medicine amendments in the context of the respective standard treatment guideline (STG) and supporting documents.

**A: AMENDMENTS**

SECTION	MEDICINE/MANAGEMENT	ADDED/DELETED/AMENDED	
<b>19. Contact Information</b>	SAVP contact details	Amended	
<b>19.1 Insect bites and stings</b>	Paracetamol dose	Amended	
<b>19.2 Snakebites</b>	General measures	Editorial amendment	
	Tetanus toxoid vaccine	Guidance added	
	Severe pain	Editorial amendment	
<b>19.2.1 Cytotoxic and neurotoxic snakebite</b>	Polyvalent snake antivenom	Guidance amended	
<b>19.2.3 Snake venom in the eye</b>	Local anaesthetic, ophthalmic drops	Added as a therapeutic class	
	Tetracaine 1%, ophthalmic drops	Retained as an example of class in the STG	
	Oxybuprocaine 0.4%, ophthalmic drops	Added to TI database	
<b>19.3 Scorpion envenomation</b>	Paracetamol	Indication amended	
	Tetanus toxoid vaccine	Guidance added	
	Calcium gluconate 10%	Retained	
<b>19.4 Spider envenomation</b>	General measures	Amended	
	Tetanus toxoid vaccine	Guidance added	
	Calcium gluconate 10%	Retained	
<b>19.5.1 Paracetamol poisoning</b> <i>- Repeated supratherapeutic ingestion (RSTI)</i>	RSTI toxic doses	Amended	
	<i>- N-acetylcysteine IV unavailable</i>	N-acetylcysteine, oral	Retained
	<i>- iatrogenic poisoning of paracetamol, IV formulations</i>	Guidance	Not added
<b>19.5.2 Salicylate poisoning</b>	Dextrose 50%, IV	Added	
<b>19.5.3 Opioid poisoning</b>	Naloxone	Guidance amended	
<b>19.6.1 Tricyclic antidepressant poisoning</b>	Description	Editorial amendment	
<b>19.7 Iron poisoning</b>	Deferoxamine (Desferrioxamine) – IM administration	Added	
	Deferoxamine (Desferrioxamine) – IV administration	Guidance clarified	
<b>19.11 Calcium channel blocker and Beta blocker poisoning</b>	High-dose Insulin Euglycaemic Therapy (HIET):	Not added	
<b>19.14 illicit drugs</b>			
<b>19.14.1 Cocaine Poisoning</b>	Benzodiazepines	Editorial amendment	
	Caution – beta-blockers	Amended	
<b>19.17.2 Ethylene glycol poisoning</b>	Ethanol	Dose and directions for use amended	
	Routine monitoring of ethanol levels	Not added	
<b>19.18.Pesticides and rodenticides</b>	Notifiable condition	Guidance added	
<b>19.18.1 Amitraz poisoning</b>			
<b>19.18.2 Organophosphate poisoning</b>	Notifiable condition	Guidance added	
	Atropine, bolus IV	Dose amended	
	Atropine, IV infusion	Directions for use amended	

<b>19.18.3 Paraquat poisoning</b>	Notifiable condition	Guidance added
	Description	Editorial amendment
<b>19.19 Anticoagulant (Warfarin and rodenticide superwarfarin) poisoning</b>	Notifiable condition	Guidance added
	Medicine treatment	Guidance amended
<i>-Superwarfarin poisoning</i>	Vitamin K1	Guidance added
<b>19.21 Heavy metal poisoning</b>	Description	Editorial amendment

## B: CLINICAL EDITORIAL AMENDMENTS

The associated EML chapter has been subject to clinical editorial review following NEMLC ratification of the chapter. These amendments have been incorporated at the end of the NEMLC report.

### 19. CONTACT INFORMATION

South African Vaccine Producers (SAVP): *amended*

Contact details for procurement of snake, spider and scorpion antivenom has been updated in consultation with the SAVP and Poisons information Centre.

### 19.1 INSECT BITES AND STINGS

Paracetamol dose: *Amended*

The dosing guidance for paracetamol for pain management has been aligned to guidance included in the PHC and AH Pain chapters. The chapter has been updated where relevant as tabulated below:

#### AMENDED FROM:

For pain:

- Paracetamol, oral, 1 g 4–6 hourly when required.
  - Maximum dose: 15 mg/kg/dose.
  - Maximum daily dose: 4 g in 24 hours.

#### AMENDED TO:

For pain:

- Paracetamol, oral, 500mg -1 g 4–6 hourly when required (to a maximum of 4 g in 24 hours)
- Maximum dose: 15 mg/kg/dose.

### 19.2 SNAKE BITES

General measures: *editorial amendment*

The following statement was added to the STG to avoid unnecessary fasciotomies as true compartment syndrome is rare:

True compartment syndrome is extremely rare in cytotoxic snakebites, as swelling is localised to the subcutaneous tissues. Fasciotomy is seldom indicated.

Tetanus toxoid vaccine: *guidance added*

Guidance for the administration of tetanus toxoid vaccine has been added to align with the PHC Chp 13: Immunisation and PHC Chp 21: Emergencies and Injuries chapters, i.e. tetanus vaccination indicated if not previously immunised within the last 5 years, as tabulated below:

» Immunisation, primary or booster: (Z23.5)

- Tetanus toxoid vaccine, IM, 0.5 mL immediately, if not previously immunised within the last 5 years.

Severe pain: *editorial amendments*

The STG has been amended editorially as tabulated below:

**AMENDED FROM:**For severe pain:**ADD**

- Morphine, IV, to a total maximum dose of 10 mg (See Appendix II, for individual dosing and monitoring for response and toxicity).
  - Opioids should be used cautiously in neurotoxic snakebite.

LoE:IVb

**Note:** The use of NSAIDs is not recommended due to the antiplatelet effect and the potential danger of renal failure in a hypotensive patient.

**AMENDED TO:**For severe pain:**ADD**

- Morphine, IV, to a total maximum dose of 10 mg (See Appendix II, for individual dosing and monitoring for response and toxicity).

**CAUTION**

Opioids increase the risk of respiratory depression particularly for neurotoxic envenomation, and if required, should only be used with caution in severe uncontrolled pain.

**Note:** NSAIDs are not recommended as they increase the risk of bleeding and renal failure, especially in patients with severe cytotoxic bites.

**19.2.1 CYTOTOXIC AND NEUROTOXIC SNAKEBITE**Polyvalent antivenom: guidance amended

Guidance on the use of polyvalent antivenom has been aligned to the updated National Snakebite Advisory Group (NSAG) and the South African Snakebite Symposium (SASS) guidelines.<sup>1</sup> Guidance on the reconstitution of antivenom has been amended i.e. 200mL of sodium chloride 0.9% is recommended instead of 100mL in view of the viscosity of the antivenom concentrate.

Indications for polyvalent antivenom:

- Signs of neurotoxicity.
- Positively identified puff adder, Gaboon adder, Mozambique spitting cobra or rinkhals bites AND evidence of progressive severe cytotoxicity.
- Unidentified snakebite AND evidence of progressive severe cytotoxicity.
- Severe local cytotoxicity is defined as:
  - swelling of whole hand or foot within 1 hour
  - swelling to the knee or elbow in less than 6 hours (or two joints above the bite site in 6 hours)
  - swelling of the whole limb in less than 12 hours
  - swelling progression ~~>2.5cm per hour~~ >5 cm per hour
  - discolouration of the skin / necrosis at the bite site
  - a threatened airway due to swelling
  - evidence of complication e.g. compartment syndrome
  - Additional features of severe systemic cytotoxicity include:
    - haematological abnormalities: Hb <8 g/dL, thrombocytopenia, (<100 x 10<sup>9</sup>/L), raised INR or abnormal thromboelastography (if available)
    - arrhythmias (rare).
    - Shock

LoE:IVb

**Note:** Polyvalent antivenom is ineffective against the venom of: night adders, berg adders and other smaller adders, boomslang, and vine/twig snakes.

**Caution**

Never administer antivenom without being prepared to manage acute anaphylaxis.

<sup>1</sup> Hardcastle TC et al (progressive cytotoxic envenomation). Approach to the diagnosis and management of snakebite envenomation in South Africa in humans: The hospital phase – emergency unit general principles. SAMJ June 2023 Vol 113, No6.

#### Administration and polyvalent antivenom dose:

Pre-treat with adrenaline (epinephrine), SC, 0.25 mL of 1:1000 solution.

**Note:** (Contraindicated in patients with IHD, stroke, uncontrolled hypertension, and tachyarrhythmia).

Polyvalent snake antivenom, slow IV infusion.

- This guidance refers to the antivenom produced by South African Vaccine Producers. For any other product refer to the relevant package insert for guidance.
- 1 ampoule contains 10 mL antivenom.
- Cytotoxic snakebite (unidentified snake): give 50 mL,
- For puff adder bites: the initial dose is 80 mL.
- For Mozambique spitting cobras the initial dose is 100 mL
- Neurotoxic snakebite: give 80–100 mL (and up to 200 mL in black mamba bites).
- ~~Mozambique spitting cobras, give 100 mL initially, preferably within 6 hours of the bite.~~
- Dilute in sodium chloride, 0.9%, 200mL; for example, if 8 ampoules are required, remove 80 mL from 200 ml saline bag and replace with 80 mL antivenom.
- Administer IV, over 30 minutes.
- Reassess once the infusion is completed. A repeat dose may be given if there is ongoing neurotoxicity or cytotoxicity

### 19.2.3 SNAKE VENOM IN THE EYE

#### **Venom in the eyes**

Local anaesthetic, ophthalmic drops: *added as a therapeutic class*

Tetracaine 1%, ophthalmic drops: *retained as an example of class in the STG*

Oxybuprocaine hydrochloride 0.4%, ophthalmic drops: *Added to TI database*

Added as an example of class to the therapeutic interchange database. Aligned with section 18.8: Surgical and diagnostic products of chapter 18: Eye conditions of the Adult Hospital Level STGs and EML, 2019 edition and PHC Chp 18 Eye conditions.

### 19.3 SCORPION ENVENOMATION

#### **Analgesia**

Paracetamol: *indication amended*

Guidance provided for mild pain management with paracetamol and management with severe local pain with lidocaine infiltration. The STG text was amended as follows

#### **For mild pain:**

- Paracetamol, oral, 500mg -1 g 4–6 hourly when required (to a maximum of 4 g in 24 hours)
  - Maximum dose: 15 mg/kg/dose.

#### **Severe local pain:**

Application of ice, if tolerated.

- Lidocaine 1–2%, 2 mL: infiltrate affected area as a local anaesthetic.

Tetanus toxoid vaccine: *guidance added*

Guidance for the administration of tetanus toxoid vaccine has been added to align with the PHC Chp 13: Immunisation and PHC Chp 21: Emergencies and Injuries chapters, i.e. tetanus vaccination indicated if not previously immunised within the last 5 years, as tabulated below:

» Immunisation, primary or booster: (Z23.5)

- Tetanus toxoid vaccine, IM, 0.5 mL immediately, if not previously immunised within the last 5 years.

Calcium gluconate 10%: *retained*

Guidance on the use of calcium gluconate 10% for the management of severe muscle pain and cramps following scorpion envenomation has been retained and a supporting reference has been added.<sup>2</sup> Calcium chloride is retained in the therapeutic interchange database although the dosing guidance is not equivalent to calcium gluconate 10%.

<sup>2</sup> Muller, G J et al. Scorpion sting in southern Africa: diagnosis and management. Continuing Medical Education, [S.l.], v. 30, n. 10, p. 356-361, sep. 2012. ISSN 2078-5143. Available at: <<http://www.cmej.org.za/index.php/cmej/article/view/2545/2580>>. Date accessed: 18 Apr. 2023.

Furthermore, calcium chloride is associated with local irritation and may cause extravasation when used intravenously, so use is generally limited to situations where IV lines to larger vessels are accessible. A maximum recommended dose of 2 grams<sup>3,4</sup> has been added to the EML. Amendments to the EML are as tabulated below:

**AMENDED FROM:**

Severe muscle pain and cramps:

- Calcium gluconate 10%, bolus IV infusion, 10 mL over 10 minutes.
  - Repeat if needed, only once

**Note:** Effect may only last for 20–30 minutes and there is a limited amount that can be given.

**AMENDED TO:**

Severe muscle pain and cramps:

Calcium gluconate 10%, bolus IV infusion, 10 mL over 10 minutes.

- Repeat if needed, only once i.e. maximum recommended dose of 2 grams.
- Note: Effect may only last for 20–30 minutes and there is a limited amount that can be given.

## 19.4 SPIDER ENVENOMATION

General measures: *Amended*

The PHC/Adult Hospital Level Committee was of the opinion that asymptomatic individuals who are well after at most 12 hours, should be able to go home, whilst individuals with neurotoxicity, should be observed for at least 24 hours. The STG text was amended as follows:

Observe all cases of potential neurotoxic spider bite for at least ~~12~~ 24 hours.

**Level of Evidence: Expert opinion**

Tetanus toxoid vaccine: *guidance added*

Guidance for the administration of tetanus toxoid vaccine has been added to align with the PHC Chp 13: Immunisation and PHC Chp 21: Emergencies and Injuries chapters, i.e. tetanus vaccination indicated if not previously immunised within the last 5 years, as tabulated below:

» Immunisation, primary or booster: (Z23.5)

- Tetanus toxoid vaccine, IM, 0.5 mL immediately, if not previously immunised within the last 5 years.

Calcium gluconate 10%: *retained*

Guidance on the use of calcium gluconate 10% for the management of severe muscle pain and cramps following spider envenomation has been retained and a supporting reference has been added.<sup>5</sup> Calcium chloride is retained in the therapeutic interchange database although the dosing guidance is not equivalent to calcium gluconate 10%. Furthermore, calcium chloride is associated with local irritation and may cause extravasation when used intravenously, so use is generally limited to situations where IV lines to larger vessels are accessible. A maximum recommended dose of 2 grams<sup>6,7</sup> has been added to the EML, as detailed in Section 19.3 Scorpion envenomation above.

## 19.5.1 PARACETAMOL POISONING

**Repeated supratherapeutic ingestion (RSTI)**

RSTI toxic doses: *amended*

The guidance defining RSTI toxic doses was updated, aligned with the updated guidelines for the management of paracetamol poisoning by Chieu et al (2020)<sup>8</sup>. STG text was amended from:

<sup>3</sup> Package Insert: Calcium Gluconate Injection Fresenius solution for injection. Fresenius Kabi Manufacturing SA (Pty) Ltd. Last revised 7 February 2023.

<sup>4</sup> Shann F. Drug doses: 17th Edition. 2017.

<sup>5</sup> MULLER, G J et al. Spider bite in southern Africa: diagnosis and management. Continuing Medical Education, [S.l.], v. 30, n. 10, p. 382-391, sep. 2012. ISSN 2078-5143. Available at: <<http://www.cmej.org.za/index.php/cmej/article/view/2547/2582>>. Date accessed: 18 Apr. 2023.

<sup>6</sup> Package Insert: Calcium Gluconate Injection Fresenius solution for injection. Fresenius Kabi Manufacturing SA (Pty) Ltd. Last revised 7 February 2023.

<sup>7</sup> Shann F. Drug doses: 17th Edition. 2017.

<sup>8</sup> Chiew AL, Reith D, Pomerleau A, Wong A, Isoardi KZ, Soderstrom J, Buckley NA. Updated guidelines for the management of paracetamol poisoning in Australia and New Zealand. Med J Aust. 2020 Mar;212(4):175-183. <https://pubmed.ncbi.nlm.nih.gov/31786822/>

RSTI toxic doses are defined as:

- » ~~>200 mg/kg or 10 g (whichever is less) over a single 24-hour period.~~
- » ~~>150 mg/kg or 6 g (whichever is less) per 24-hour period for the preceding 48 hours.~~
- » ~~>100 mg/kg or 4 g/day (whichever is less) per 24-hour period for more than 48 hours and patients have symptoms suggestive of liver injury.~~

To:

RSTI toxic doses are defined as:

- » >200 mg/kg or 10 g (whichever is less) over a single 24-hour period.
- » >300 mg/kg or 12 g (whichever is less) over a single 48-hour period.
- » >60 mg/kg/day for more than 48 hours and patients have symptoms suggestive of liver injury.

AGREE 2 assessment of these updated guidelines scored a mean score of 5/7 (4/7 and 6/7 by respective reviewers). There is general overall agreement to recommend use of these guidelines in the South African setting, with modification. The rigour of development of these guidelines, however was questioned.

**Level of Evidence: Low certainty, strong recommendation**

**If N-acetylcysteine IV is unavailable:**

N-acetylcysteine, oral: *retained*

Oral dose of N-acetylcysteine was confirmed to be correct - NEMLC-approved in the previous review cycle of the Adult Hospital Level STGs and EML, 2019 – see NEMLC report below:

***NEMLC report for the Adult Hospital Level Emergencies and injuries chapter (2017-9 review cycle):***

*N-acetylcysteine, oral: retained and dosing regimen added*

*Where parenteral formulation is unavailable, oral NAC recommended as a safe alternative where IV administration is not an option. Previous recommendation of oral NAC if IV formulation is unavailable has been expanded to include a dosing regimen, as follows:*

*If N-acetylcysteine, IV is unavailable:*

- *N-acetylcysteine, oral, 140 mg/kg, followed by 70 mg/kg 4 hourly for seventeen doses.*

**Note:** Avoid giving activated charcoal if giving N-acetylcysteine orally as it will reduce the systemic absorption and thus negate the effect of oral N-acetylcysteine.

**Level of Evidence: III Observational studies<sup>9 10 11</sup>**

**Recommendation:** Guidance for oral NAC to be updated in the PHC STGs and EML.

Updates to the STG are as tabulated below:

**AMENDED FROM:**

#### **MEDICINE TREATMENT**

N-acetylcysteine is the antidote of choice and should be given intravenously. Although it is more effective when given within 8 hours of ingestion of paracetamol, there may be benefit even if liver failure has developed.

Histamine may be released, which mimics an allergic reaction. If this occurs and the patient is stable, infusion may continue at a slower rate under antihistamine cover. In the presence of bronchospasm, stop the infusion.

- N-acetylcysteine, IV:
  - Initial infusion: 200 mg/kg in 500 mL 5% dextrose over 4 hours
  - Second infusion: 100 mg/kg in 1000 mL 5% dextrose over 16 hours.
  - Any further N-acetylcysteine is given according to the second infusion regimen.

If N-acetylcysteine, IV is unavailable:

- N-acetylcysteine, oral, 140 mg/kg, followed by 70 mg/kg 4 hourly for seventeen doses.

**Note:** Avoid giving activated charcoal if using oral N-acetylcysteine, as it will reduce systemic absorption of the antidote.

#### **Further investigations and referral**

- Blood tests such as renal function, clotting profile, serum glucose and acid/base status should only be done where clinically indicated.

**Patients who develop liver failure must be referred for further management and/or possible transplant**

<sup>9</sup> Yarema MC, Johnson DW, Berlin RJ, Sivilotti ML, Nettel-Aguirre A, Brant RF, Spyker DA, Bailey B, Chalut D, Lee JS, Plint AC, Pursell RA, Rutledge T, Seviour CA, Stiell IG, Thompson M, Tyberg J, Dart RC, Rumack BH. Comparison of the 20-hour intravenous and 72-hour oral acetylcysteine protocols for the treatment of acute acetaminophen poisoning. *Ann Emerg Med.* 2009 Oct;54(4):606-14. <https://www.ncbi.nlm.nih.gov/pubmed/19556028>

<sup>10</sup> Williamson K, Wahl MS, Mycyk MB. Direct comparison of 20-hour IV, 36-hour oral, and 72-hour oral acetylcysteine for treatment of acute acetaminophen poisoning. *Am J Ther.* 2013 Jan;20(1):37-40. <https://www.ncbi.nlm.nih.gov/pubmed/23299230>

<sup>11</sup> Rumack and Bateman. Acetaminophen and acetylcysteine dose and duration: past, present and future. *Clin Toxicol (Phila)* 2012;50(2):91-98. <https://www.ncbi.nlm.nih.gov/pubmed/22320209>

**AMENDED TO:  
MEDICINE TREATMENT**

N-acetylcysteine is the antidote of choice and should be given intravenously. Although it is more effective when given within 8 hours of ingestion of paracetamol, there may be benefit even if liver failure has developed. Histamine may be released, which mimics an allergic reaction. If this occurs and the patient is stable, infusion may continue at a slower rate under antihistamine cover. Stop the infusion if bronchospasm occurs.

N-acetylcysteine, IV:

- Initial infusion: 200 mg/kg in 500 mL dextrose, 5% over 4 hours.
- Second infusion: 100 mg/kg in 1000 mL dextrose, 5% over 16 hours.
- Any further N-acetylcysteine is given according to the second infusion regimen.

If N-acetylcysteine IV formulation is unavailable:

N-acetylcysteine, oral, 140 mg/kg immediately.

- Followed by 70 mg/kg 4 hourly, for up to seventeen doses.

**Note:**

As anaphylactoid reactions to N-acetylcysteine do occur, the loading dose should preferably be administered in a monitored area. Avoid giving oral N-acetylcysteine together with activated charcoal as systemic absorption and effect of N-acetylcysteine is reduced.

**Further investigations and referral**

- » Blood tests such as renal function, clotting profile, serum glucose and acid/base status should only be done where clinically indicated.
- » Patients who develop liver failure must be referred for further management and/or possible transplant.

**Poisoning of paracetamol, IV formulations**

Guidance on iatrogenic poisoning of paracetamol, IV formulations: not added

Guidance for iatrogenic poisoning of paracetamol, IV formulations was not included in the STG. At the time of review the AH Chp 19 Poisoning chapter, paracetamol, IV was not approved as an EML medicine.

**19.5.2 SALICYLATE POISONING**

Dextrose 50%, IV: added

Dextrose-containing fluids were included in the STG for hydration. Two case reports suggests that dextrose infusions with boluses may improve salicylate-induced delirium in euglycaemic patients.<sup>12</sup>

**Level of Evidence: Case reports**

The EML has been updated as tabulated below:

<b>AMENDED FROM :</b>	<b>AMENDED TO :</b>																									
<b>19.5.2 SALICYLATE POISONING</b>	<b>19.5.2 SALICYLATE POISONING</b>																									
<p><b>Diagnosis:</b> <u>Mild to moderate toxicity:</u> » Nausea, vomiting, tinnitus, fever, tachypnoea, and respiratory alkalosis</p> <p><u>Severe toxicity:</u> » Metabolic acidosis, altered mental status, seizures, coma, non-cardiogenic pulmonary oedema. » Monitor salicylate levels if possible (do not always correlate with clinical severity):</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th rowspan="2">Severity of toxicity</th> <th colspan="2">Peak plasma salicylate concentrations</th> </tr> <tr> <th>mmol/L</th> <th>mg/dL</th> </tr> </thead> <tbody> <tr> <td>Asymptomatic</td> <td>&lt;2.2 mmol/L</td> <td>&lt;30 mg/dL</td> </tr> <tr> <td>Mild toxicity</td> <td>2.2-4.3 mmol/L</td> <td>30-60 mg/dL</td> </tr> <tr> <td>Moderate toxicity</td> <td>4.3-5.8 mmol/L</td> <td>60-80 mg/dL</td> </tr> <tr> <td>Severe toxicity</td> <td>&gt;5.8 mmol/L</td> <td>&gt;80 mg/dL</td> </tr> </tbody> </table> <p><b>Table 19.3:</b> Severity of toxicity by peak plasma salicylate concentrations.</p>	Severity of toxicity	Peak plasma salicylate concentrations		mmol/L	mg/dL	Asymptomatic	<2.2 mmol/L	<30 mg/dL	Mild toxicity	2.2-4.3 mmol/L	30-60 mg/dL	Moderate toxicity	4.3-5.8 mmol/L	60-80 mg/dL	Severe toxicity	>5.8 mmol/L	>80 mg/dL	<p><b>Diagnosis:</b> <u>Mild toxicity:</u> » Nausea, vomiting, tinnitus, fever, lethargy, dizziness</p> <p><u>Moderate toxicity:</u> » Sweating, restlessness, dehydration, hyperventilation, respiratory alkalosis with or without metabolic acidosis</p> <p><u>Severe toxicity:</u> » Metabolic acidosis, altered mental status, seizures, coma, non-cardiogenic pulmonary oedema.</p> <p><b>GENERAL MEASURES</b> » Assess severity with history, clinical examination. » Monitor salicylate levels if possible (do not always correlate with clinical severity):</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th rowspan="2">Severity of toxicity</th> <th colspan="2">Peak plasma salicylate concentrations</th> </tr> <tr> <th>mmol/L</th> <th>mg/dL</th> </tr> </thead> <tbody> <tr> <td>Asymptomatic</td> <td>&lt;2.2 mmol/L</td> <td>&lt;30 mg/dL</td> </tr> </tbody> </table>	Severity of toxicity	Peak plasma salicylate concentrations		mmol/L	mg/dL	Asymptomatic	<2.2 mmol/L	<30 mg/dL
Severity of toxicity		Peak plasma salicylate concentrations																								
	mmol/L	mg/dL																								
Asymptomatic	<2.2 mmol/L	<30 mg/dL																								
Mild toxicity	2.2-4.3 mmol/L	30-60 mg/dL																								
Moderate toxicity	4.3-5.8 mmol/L	60-80 mg/dL																								
Severe toxicity	>5.8 mmol/L	>80 mg/dL																								
Severity of toxicity	Peak plasma salicylate concentrations																									
	mmol/L	mg/dL																								
Asymptomatic	<2.2 mmol/L	<30 mg/dL																								

<sup>12</sup> Kuzak N, Brubacher JR, Kennedy JR. Reversal of salicylate-induced euglycemic delirium with dextrose. Clin Toxicol (Phila). 2007 Jun-Aug;45(5):526-9. <https://pubmed.ncbi.nlm.nih.gov/17503260/>

- » Serial monitoring until declining levels are documented.
- » Monitor and treat hypoglycaemia; patients with normoglycaemia may still be neuroglycopenic.

### GENERAL MEASURES

- » Assess severity with history, clinical examination, and salicylate levels if possible.
- » Correct hydration using dextrose-containing fluids.
- » Ensure hypokalaemia treated early
- » Consider ICU admission for pulmonary and/or cerebral oedema.

### MEDICINE TREATMENT

- Salicylates delay gastric emptying, therefore activated charcoal may be effective for a longer period than usual.
- Whole bowel irrigation maybe useful for enteric-coated or modified-release preparations.

#### For hydration:

- Dextrose 5%, IV.

#### Treat acidosis and enhance renal excretion:

- Sodium bicarbonate 8.4%, IV and urinary alkalinisation (blood pH 7.45-7.5 and urine pH 7.5–8.5) in consultation with specialist and arrange for transfer.

### REFERRAL

Where acidosis does not respond to sodium bicarbonate, refer for haemodialysis.

Mild toxicity	2.2-4.3 mmol/L	30-60 mg/dL
Moderate toxicity	4.3-5.8 mmol/L	60-80 mg/dL
Severe toxicity	>5.8 mmol/L	>80 mg/dL

**Table 19.3:** Severity of toxicity by peak plasma salicylate concentrations.

- » Serial monitoring of salicylate levels until declining levels are documented.
- » Monitor and treat hypoglycaemia; patients with normoglycaemia may still be neuroglycopenic.
- » Ensure hypokalaemia treated early
- » Consider ICU admission for pulmonary and/or cerebral oedema.

### MEDICINE TREATMENT

- » Salicylates delay gastric emptying, therefore activated charcoal may be effective for a longer period than usual.
- » Whole bowel irrigation maybe useful for enteric-coated or modified-release preparations.

#### For mild toxicity:

- Rehydrate and correct hypovolaemia with dextrose-containing fluids.
  - Add dextrose 50%, 100mL to every litre of balanced crystalloid solution (e.g. ringers lactate) or sodium chloride 0.9%, and administer by IV infusion.
  - During preparation of the infusion fluid, ensure the equivalent volume of rehydration fluid (e.g. 100mL) is removed from the bag before adding the total dextrose 50% volume (e.g. 100mL).
  - The rate and duration of IV fluids should be guided by clinical assessment of fluid balance.

#### In patients with moderate to severe toxicity and/or acidosis:

- Sodium bicarbonate 8.4%, IV, 1–2 mL/kg over 30 minutes to manage acidosis.
- Simultaneously fluid resuscitate with sodium bicarbonate 8.4%, 150mL added to dextrose 5%, 1L and administer by IV infusion to correct hypovolaemia.
  - During preparation of the infusion fluid, ensure the equivalent volume of dextrose 5% (i.e. 150 mL) is removed from the bag before adding the total sodium bicarbonate 8.4% volume of 150 mL.
  - Continue a maintenance infusion at 150 – 200 mL/hour, targeting a urine output of 2ml/kg/hour.
  - Titrate the sodium bicarbonate maintenance infusion to a urinary pH of 7.5 – 8.5 and blood pH of 7.45 – 7.5.
  - Monitor for and correct hypokalaemia.

### REFERRAL

- » Discuss with specialist and consider ICU admission
- » Where acidosis does not respond to sodium bicarbonate, refer for haemodialysis.

## 19.5.3 OPIOID POISONING

### Naloxone: Amended

Guidance on the administration of naloxone has been amended to include the following:

- Naloxone in an opioid-dependent person may precipitate a withdrawal syndrome with agitation, hypertension, tachycardia, emesis, and potential aspiration. These patients usually require lower doses when initiating naloxone (0.04-0.1mg IV).



### 19.6.1 TRICYCLIC ANTIDEPRESSANT POISONING

Description: Editorial *amendment*

Editorial updates to the description are as tabulated below:

#### AMENDED FROM:

##### DESCRIPTION

Patients can deteriorate rapidly.

#### AMENDED TO<sup>13</sup>:

##### DESCRIPTION

TCA's may be life threatening at relatively low doses. Cardiovascular and neurological impairment are the most serious consequences of TCA toxicity, and patients can deteriorate rapidly depending on the severity.

### 19.7 IRON POISONING

Deferoxamine (desferrioxamine) - IM administration: *Added*

Deferoxamine (desferrioxamine) is registered for both IM and IV administration, and can be used in clinical practice particularly for low risk patients.<sup>14</sup> The literature supports both IM and IV administration, except for patients in cardiogenic shock when IV administration is preferred.<sup>15,16,17,18</sup> The inclusion of the IM route of administration will empower clinicians, particularly when IV access is not readily available. IM administration will also avert the insertion of unnecessary IV lines.

Deferoxamine (desferrioxamine)-IV administration: *Guidance clarified*

Dosing guidance on the administration of IV Deferoxamine (desferrioxamine) has been clarified as tabulated below:

#### AMENDED FROM:

- Desferoxamine (deferoxamine), IV infusion, 15 mg/kg/hour to a total of 80 mg/kg, i.e. given over about 6 hours. Beware of hypotension.
  - **Note:** Prolonged use >24 hours of high doses is associated with acute lung injury and should be avoided. However, in severe poisonings, additional doses may be required.
  - Desferoxamine can be used in pregnant women.

#### AMENDED TO:

Deferoxamine (desferrioxamine), IV infusion, 80 mg/kg.

- Administer at 15mg/kg/hour over about 6 hours.
- Beware of hypotension.
- **Note:** Prolonged use (>24 hours) of high doses are associated with acute lung injury and should be avoided. However, additional doses may be required in severe poisonings – A benefit-risk assessment is required in these patients.
- Where IV access is not obtainable, deferoxamine can be given by IM injection as follows: deferoxamine, IM injection 1 g immediately, followed by 500 mg every 4 to 12 hours, as needed based on clinical response.
- For cardiogenic shock, the IV route is preferred and should be used as soon as IV access is possible.
- Deferoxamine can be used in pregnant women.

### 19.11 CALCIUM CHANNEL BLOCKER AND BETA BLOCKER POISONING

High-dose Insulin Euglycaemic Therapy (HIET): *Not added*

The Committee noted that the evidence on the use of HIET as a first line therapy for the management of calcium channel blocker and/or beta blocker poisoning is evolving although much of this is limited to observational studies. Following extensive deliberation by the ERC and NEMLC, it was agreed that HIET not be included in the AH Chp 19:

<sup>13</sup> David M. Taylor, Thomas R. E. Barnes, Allan H. Young. The Maudsley prescribing guidelines in psychiatry.13th edition. Hoboken, NJ : Wiley, 2019. (page 770)

<sup>14</sup> Package Insert – Desferal. Novartis. 10 August 2006.

<sup>15</sup> Drug monograph – deferoxamine. Clinical Key. Last revised 3 October 2022. Date accessed 2 March 2023

<sup>16</sup> Drug monograph – deferoxamine. Micromedex. Last modified 22 November 2022. Date accessed 2 March 2023

<sup>17</sup> Drug monograph – deferoxamine. Statpearls. Last modified 29 May 2022. Date accessed 2 March 2023

<sup>18</sup> Drug monograph – deferoxamine. UptoDate. Date accessed 2 March 2023

Poisonings chapter, as patients receiving HIET require management in a High Care/ICU setting. The use of HIET for managing calcium channel blocker and/or beta blocker poisoning to be considered for prioritisation during the next review cycle as part of the AH Chp 23 Critical Care review.

Updates to the STG are as tabulated below:

AMENDED FROM	AMENDED TO
<p><b>19.11 CALCIUM CHANNEL BLOCKER AND BETA BLOCKER POISONING</b></p> <p><b>DESCRIPTION</b> Cardiovascular toxicity results in profound hypotension, bradycardia, decreased systemic vascular resistance and cardiogenic shock. Depressed level of consciousness and metabolic acidosis are due to poor tissue perfusion. Hyperglycaemia and hypokalaemia may occur. Patients who have co-ingested other cardiac medicines and those with pre-existing cardiac disease are at increased risk of morbidity.</p> <p>The treatment of suspected cardiogenic shock in calcium channel blocker and beta blocker poisoning follows similar therapeutic principles. The mainstay of treatment is high-dose insulin euglycaemia therapy (HIET) and inotrope and vasopressor infusions.</p> <p><b>GENERAL MEASURES</b> Monitor vital signs, ECG and blood glucose. Treat symptomatic patients in consultation with a specialist.</p> <p><b>MEDICINE TREATMENT</b></p> <ul style="list-style-type: none"> <li>» Caution is advised for all decontamination procedures as they increase vagal tone and may exacerbate bradycardia.</li> <li>» Activated charcoal may be considered before the onset of symptoms.</li> <li>» Whole bowel irrigation can be considered for ingestion of modified-release preparations.</li> </ul> <p><u>Treat hypotension:</u> I95.9 + (T46.1/X44.99/X64.99/Y14.99)</p> <ul style="list-style-type: none"> <li>• Sodium chloride 0.9%, IV.</li> </ul> <p><u>If hypotension not effectively controlled add:</u></p> <ul style="list-style-type: none"> <li>• Calcium gluconate 10%, IV, 30–60 mL given over 15–30 minutes, with ECG monitoring. <ul style="list-style-type: none"> <li>○ This may be repeated a maximum of 4 times.</li> </ul> </li> </ul> <p><u>Treat bradycardia:</u> R00.1 + (T46.1/X44.99/X64.99/Y14.99)</p> <ul style="list-style-type: none"> <li>• Atropine, IV 0.5–1 mg every 2–3 minutes to a maximum of 3 mg.</li> </ul> <p>Simultaneously use vasopressors and inotropes as needed, e.g. adrenaline (epinephrine) infusion for persistent hypotension (section 20.1: Cardiac arrest) or dobutamine for bradycardia (section 20.1.5: Cardiogenic shock).</p> <p><b>REFERRAL</b> Refer for management with high dose insulin for resistant hypotension and bradycardia, in a high care or ICU setting.</p> <p><u>If glucose &lt;10 mmol/L:</u></p> <ul style="list-style-type: none"> <li>• Dextrose 50%, IV, 50 mL</li> </ul> <p>Followed by:</p> <ul style="list-style-type: none"> <li>• Insulin, short acting, IV, 1 unit/kg. <ul style="list-style-type: none"> <li>○ Followed by 0.5 unit/kg/hour.</li> <li>○ Titrate dose up until hypotension is corrected, to maximum 10 units/kg/hour.</li> </ul> </li> </ul> <p>Monitor and correct potassium and glucose.</p>	<p><b>19.11 CALCIUM CHANNEL BLOCKER AND BETA BLOCKER POISONING</b></p> <p><b>DESCRIPTION</b> Cardiovascular toxicity results in profound hypotension, bradycardia, decreased systemic vascular resistance and cardiogenic shock. Depressed level of consciousness and metabolic acidosis are due to poor tissue perfusion. Hyperglycaemia and hypokalaemia may occur. Patients who have co-ingested other cardiac medicines and those with pre-existing cardiac disease are at increased risk of morbidity.</p> <p>The treatment of suspected cardiogenic shock in calcium channel blocker and beta blocker poisoning follows similar therapeutic principles. The mainstay of treatment is high-dose insulin euglycaemic therapy (HIET) and inotrope and vasopressor infusions.</p> <p><b>GENERAL MEASURES</b></p> <ul style="list-style-type: none"> <li>» Monitor vital signs, ECG, and blood glucose.</li> <li>» Treat symptomatic patients in consultation with a specialist.</li> </ul> <p><b>MEDICINE TREATMENT</b></p> <ul style="list-style-type: none"> <li>» Caution is advised for all decontamination procedures as they increase vagal tone and may exacerbate bradycardia.</li> <li>» Activated charcoal may be considered before the onset of symptoms.</li> <li>» Whole bowel irrigation can be considered for ingestion of modified-release preparations.</li> </ul> <p><b>Bradycardia:</b> R00.1 + (T46.1/X44.99/X64.99/Y14.99)</p> <ul style="list-style-type: none"> <li>• Atropine, IV 0.5–1 mg every 2–3 minutes to a maximum of 3 mg.</li> </ul> <p><b>Hypotension:</b> I95.9 + (T46.1/X44.99/X64.99/Y14.99)</p> <ul style="list-style-type: none"> <li>• <b>Start with</b> sodium chloride, 0.9%, IV.</li> </ul> <p><u>If not effectively controlled add:</u></p> <ul style="list-style-type: none"> <li>• Calcium gluconate 10%, IV, 30–60 mL given over 15–30 minutes, with ECG monitoring. <ul style="list-style-type: none"> <li>○ This may be repeated a maximum of 4 times.</li> </ul> </li> <li>• Simultaneously use vasopressors and inotropes as needed, e.g. adrenaline (epinephrine) infusion for persistent hypotension (section 20.1: Cardiac arrest in adults) or dobutamine for bradycardia (section 20.11.3: Cardiogenic shock) <b>and refer patient immediately.</b></li> </ul> <p><b>REFERRAL</b> <b>All patients requiring HIET should be treated in a High Care or ICU setting.</b></p>

## 19.14 ILLICIT DRUGS

### 19.14.1 COCAINE POISONING

#### Medicine treatment – benzodiazepines: *Editorial amendment*

The following statement has been added to the STG to highlight the therapeutic value of benzodiazepines which included sympathetic stimulation: “Benzodiazepines play a key role in the management of sympathetic and psychomotor features of cocaine poisoning.”

#### Caution – beta-blockers: *Amended*

The caution with the use of beta-blockers has been amended as tabulated below:

##### AMENDED FROM:

β-blockers should not be used.

##### AMENDED TO:

##### CAUTION

β-blockers (other than labetalol) may worsen vasoconstriction and should not be used.

### 19.17.2 ETHYLENE GLYCOL POISONING

#### Ethanol: *dose and directions for use amended*

**Background:** Errors were detected in the Adult Hospital Level STG s and EML, 2019 regarding management in this clinical setting. An erratum was subsequently circulated by NDoH:



AdultHospitalLevelS  
TGErrata\_EthyleneGI

Subsequent to the erratum that was issued, comments were received that the guidance on the dilution and administration of ethanol was not clear. Following a pilot of several alternatives, the guidance was amended as below for improved clarity. The NEMLC would like to encourage ongoing comment/suggestions from clinicians to improve clarity and eliminate any ambiguity with interpreting the STG.

##### Amended from (circular):

- Ethanol ~~95%~~ 96% BP, oral,
  - Loading dose 1 mL/kg.
  - Dilute the calculated ethanol volume to 20% (1 part ethanol to 4 parts juice or water) and give over 15-30 minutes.
  - Maintenance dose:
    - non-drinker: 0.125 mL/kg/hour
    - chronic drinker: 0.2 mL/kg/hour
  - Dilute the calculated ethanol volume to 20% (1 part ethanol to 4 parts juice or water)
- OR
- Ethanol 40% v/v (gin, whiskey, vodka), oral
  - Loading dose: 2 mL/kg
  - Dilute the calculated ethanol volume to 20% (1 part ethanol to 1 part juice or water) and give over 15-30 minutes
  - Maintenance dose:
    - non-drinker: ~~25~~ 0.25 mL/kg/hour
    - chronic drinker: 0.5 mL/kg/hour
  - Dilute the calculated ethanol volume to 20% (1 part ethanol to 1 part juice or water)

##### Amended to:

##### Ethanol

##### Indications:

History of ingestion, plus any two of the following criteria:

- Arterial pH <7.3

- Serum bicarbonate <20 mmol/L
- Presence of urinary oxalate crystals (ethylene glycol only) or visual disturbances (methanol only)

Preparation and administration of ethanol:

**Step 1: Prepare an ethanol 20% solution:**

If using Ethanol 96% BP, oral,

- Add 1 part ethanol 96% to 4 parts juice or water e.g. 250 mL of ethanol 96% with 1000mL water or juice to give a total volume of 1250 mL ethanol 20%.

If using Ethanol 40% v/v (gin, whiskey, vodka), oral

- Add 1 part ethanol 40% to 1 part juice or water e.g. dilute 500mL of ethanol 40% with 500mL water or juice to give a total volume of 1000mL ethanol 20%.
- **Note:** Spirit liquor products in South Africa are frequently bottled at 43% v/v. These can be used interchangeably.

**Step 2: Administer a loading dose:**

- Ethanol 20% (the solution prepared in Step 1), oral, 4 mL/kg over 15-30 minutes.

**Step 3: Continue with maintenance doses:**

- Ethanol 20% (the solution prepared in Step 1), oral:
- Non-drinker: 0.5 mL/kg/hour
- Chronic drinker: 1 mL/kg/hour

**WORKED EXAMPLES**

**For a 60kg patient who is a non-drinker**

**Loading dose:** 240 ml of the ethanol 20% solution orally over 15-30 minutes.

**Maintenance dose:** 30 mL per hour orally of the ethanol 20% solution.

**For a 60kg patient who is a chronic drinker**

**Loading dose:** 240 ml of the ethanol 20% solution orally over 15-30 minutes.

**Maintenance dose:** 60 mL per hour orally of the ethanol 20% solution.

**Note:**

- If patients are not co-operative, administer ethanol via a nasogastric tube.

**CAUTION**

Locally available commercial ethanol products are not approved for IV administration and should not be administered via this route.

- Maintain ethanol levels of 1–1.3 g/L (100–130 mg/dL).
- Where ethylene glycol, methanol (see Section 19.17.3: Methanol poisoning), and ethanol levels are not available for monitoring purposes, titrate the ethanol rate of administration according to improvement in metabolic acidosis and signs of systemic toxicity.
- Increase the dose of ethanol if the patient is receiving concomitant haemodialysis.
- Several days of ethanol therapy may be required until clinical condition improves.
- Alcoholic beverages are sometimes labelled as "percentage proof". Alcohol proof values are double the alcohol percentage (volume/volume) values. i.e. an 80 proof alcohol would be 40% (v/v).

**Monitoring of ethanol levels**

Routine monitoring of ethanol levels: not added (for tertiary level of care)

It was reported that ethanol levels are not always readily available and thus clinical response generally guides management in practice. NHLS reported that currently only one tertiary facility requests this laboratory test. However, pre-analytical considerations are important as the blood sample needs to be spun down and sent frozen, as ethanol is oxidized.

**Recommendation:** The PHC/Adult Hospital Level Committee recommended that this test not be motivated for routine use at all tertiary level facilities as not pragmatic. However, the STG be expanded to include guidance be provided on clinical management of patients (in the absence of monitoring of ethanol levels).

**Level of Evidence: Expert opinion**

## 19.18 PESTICIDES AND RODENTICIDES

### 19.18.1 AMITRAZ POISONING

Notifiable condition: *guidance added*

Editorial guidance added to indicate that poisoning from all pesticides is a notifiable condition.

### 19.18.2 ORGANOPHOSPHATE POISONING

Notifiable condition: *guidance added*

Editorial guidance added to indicate that poisoning from all pesticides is a notifiable condition.

#### **Atropinisation**

Atropine, bolus IV: *amended*

The dose of bolus IV atropine was simplified from a range, “2-5 mg” to “2mg”.

Atropine, IV: *directions for use amended*

Expanded guidance on atropine infusion after atropinization was included.

An open-label RCT<sup>19</sup>(n=156) compared conventional bolus dose atropine (group A, n=81) to rapidly incremental doses of atropine followed by infusion (group B, n=75). The mortality was 22.5% (18/80) vs 8% (6/75) (p<0.05) and the mean duration of atropinization was 151.74 min vs 23.90 min (p<0.001). More patients in group A (compared to group B) experienced atropine toxicity (28.4% vs 12.0%, p<0.05); intermediate syndrome (13.6% versus 4%, p<0.05), and required more respiratory support (24.7% versus 8%, p<0.05). Thus, improved mortality and morbidity survival has been demonstrated in patients with organophosphate poisoning who received rapid incremental dose atropinization followed by atropine infusions.

**Level of Evidence: Low certainty, strong recommendation**

The STG text was amended as follows, but NEMLC proposed further amendments for improved clarity:

For bronchorrhoea, bronchospasm or bradycardia:

- Atropine bolus, IV, 2 mg.
  - Reassess after 3–5 minutes for evidence of atropinisation as indicated by reduced bronchial secretions, dry skin, increasing heart rate and blood pressure, and dilating pupils (note: pupil dilatation may be delayed)
  - Give repeated atropine boluses incrementally doubling the dose until adequate clinical response achieved, e.g. 2 mg, 4 mg, 8 mg, 16 mg etc.
    - If no clinical response, give double the dose.
    - If some response, give the same or reduced dose.
  - ~~Follow with infusion atropinisation with atropine, IV infusion.~~
    - Titrate according to clinical response, starting at 10% of the total bolus dose. Calculate the total dose of atropine given as boluses (as described above). Give 10–20% of this dose per hour, titrating according to clinical response.
    - e.g.: 40 mg of Atropine in 200 mL 0.9% sodium chloride (0.2 mg/mL) 10-20 mg/hour = 50-100 mL/hr.
  - Reassess frequently and adjust atropine infusion as follows:
    - Bronchial secretions, bronchospasm or bradycardia recurs: increase dose.
    - Good control of bronchial secretions and signs of atropine overdose (tachycardia, mydriasis, agitation, pyrexia, reduced bowel sounds and urinary retention): decrease dose.
    - No recurrence of bronchial secretions and no signs of atropine overdose: reduce dose slowly.

### 19.18.3 PARAQUAT POISONING

Notifiable condition: *guidance added*

Editorial guidance added to indicate that poisoning from all pesticides is a notifiable condition.

Description: *Editorial amendment*

<sup>19</sup> Abedin MJ, Sayeed AA, Basher A, Maude RJ, Hoque G, Faiz MA. Open-label randomized clinical trial of atropine bolus injection versus incremental boluses plus infusion for organophosphate poisoning in Bangladesh. *J Med Toxicol.* 2012 Jun;8(2):108-17. <https://pubmed.ncbi.nlm.nih.gov/22351300/>

The following statement has been amended to indicate that paraquat is the most toxic herbicide known<sup>20</sup>:

Paraquat is the most toxic herbicide known, and toxicity causes multi-organ failure which is often fatal.

## 19.19 ANTICOAGULANT (WARFARIN AND RODENTICIDE SUPERWARFARIN) POISONING

Notifiable condition: guidance added

Editorial guidance added to indicate that poisoning from all pesticides is a notifiable condition.

Medicine treatment: guidance amended

Guidance on the use of vitamin k for the management of warfarin poisoning was amended as tabulated below. The approved package insert for the injectable formulations of vitamin K available on tender, advise against the dilution of the IV formulation<sup>21</sup>. STG guidance has therefore been amended that vitamin k IV should be administered undiluted as a slow IV bolus injection.

Original STG text	2023 STG Amendments
<p>T45.5 + (X44.99/X64.99/Y14.99) * Notifiable condition – rodenticide superwarfarin poisoning</p> <p><b>DESCRIPTION</b> Poisoning due to ingestion of warfarin and superwarfarins, e.g. rat poison and other vermin poisons. Warfarin toxicity can occur with either acute overdose or unintentionally, during therapeutic use, whereby drug interactions increase warfarin bioavailability (e.g. concomitant enzyme inhibitor), or concomitant anticoagulant drugs are administered (e.g. NSAIDS). Bleeding is the main clinical presentation e.g. gastrointestinal or intracranial bleeding; however bleeding may be occult. Superwarfarins are more potent than warfarin and may have a long duration of effect; small doses of concentrated formulations may cause significant anticoagulation. Measure INR at baseline and 48 hours post ingestion, as the anticoagulant effect may be delayed by 1–2 days.</p> <div data-bbox="113 1137 826 1234" style="border: 1px solid black; padding: 5px;"> <p>Where the history is of an unspecified rat poison or pesticide ingestion, consider other active ingredients such as amitraz and organophosphates.</p> </div> <p><b>GENERAL MEASURES</b> Resuscitation. Stop warfarin in patients on therapy.</p> <p><b>MEDICINE TREATMENT</b> <b>For patients on warfarin therapy</b> <u>INR 5 to 9 without bleeding:</u> » Stop warfarin » Evaluate bleeding risk – <u>High risk patients:</u> (history of bleeding, stroke, renal insufficiency, anaemia, hypertension). • Vitamin K<sub>1</sub> oral, 1–2.5 mg, for 1–2 days and monitor INR. – <u>Low risk patients:</u> Monitor INR.</p> <p><u>INR &gt;9 without bleeding:</u> » Stop warfarin. • Vitamin K<sub>1</sub> oral, 2.5–5 mg, for 1–2 days and monitor INR (response usually in 24 to 48 hrs). » Resume warfarin therapy, at a lower dose.</p>	<p>T45.5 + (X44.99/X64.99/Y14.99) * Notifiable condition – rodenticide superwarfarin poisoning <b>Poisoning from all pesticides (i.e. agricultural stock remedies) is a notifiable medical condition. Please visit <a href="http://www.nicd.ac.za">www.nicd.ac.za</a> for further information.</b></p> <p><b>DESCRIPTION</b> <b>DESCRIPTION</b> Poisoning due to ingestion of warfarin and superwarfarins, e.g. rat poison and other vermin poisons. Warfarin toxicity can occur with either acute overdose or unintentionally, during therapeutic use, whereby drug interactions increase warfarin bioavailability (e.g. concomitant enzyme inhibitor), or concomitant anticoagulant drugs are administered (e.g. NSAIDS). Bleeding is the main clinical presentation e.g. gastrointestinal or intracranial bleeding; however bleeding may be occult. Superwarfarins are more potent than warfarin and may have a long duration of effect; small doses of concentrated formulations may cause significant anticoagulation.</p> <div data-bbox="863 1211 1481 1328" style="border: 1px solid black; padding: 5px;"> <p style="text-align: center;"><b>CAUTION</b></p> <p style="text-align: center;">Where the history is of an unspecified rat poison or pesticide ingestion, consider other active ingredients such as amitraz and organophosphates.</p> </div> <p><b>GENERAL MEASURES</b> • Resuscitation. • Stop warfarin in patients on therapy. • <b>Measure INR at baseline and 48 hours post ingestion, as the anticoagulant effect may be delayed by 1–2 days.</b></p> <p><b>MEDICINE TREATMENT</b> <b>Do NOT give vitamin K prophylactically. It is only indicated when there is active bleeding or a specifically raised INR (INR &gt; 4).</b></p> <p><b>Active bleeding: R58 + (T45.5/X44.99/X64.99/Y14.99)</b> • Lyophilised plasma, IV, 15 mL/kg. <b>OR</b> • Fresh Frozen Plasma, IV, 15 mL/kg.</p> <div data-bbox="1329 1765 1481 1796" style="border: 1px solid black; padding: 2px;"> <p style="text-align: right;">LoE:IIIa</p> </div> <p><b>AND</b> <b>Vitamin K<sub>1</sub>, IV, 10 mg</b></p>

<sup>20</sup> SAMF, 14<sup>th</sup> edition: Paraquat, pg 646

<sup>21</sup> Package Insert. Konakion MM. Pharmaco Distribution (Pty) Ltd. Last revision: 30 September 2011, 20 July 2018

Vitamin K<sub>1</sub> is available as a parenteral preparation only, but is safest given orally in anticoagulant poisoning.

LoE:IIIa

Elevated INR with significant bleeding: R58 + (T45.5/X44.99/X64.99/Y14.99)

» Stop warfarin.

- Lyophilised plasma, IV, 15 mL/kg.

LoE:IIIa

**OR**

FFP 15 mL/kg.

LoE:IIIa

Followed by:

- Vitamin K<sub>1</sub>, IV, 5 mg diluted in 100 mL sodium chloride 0.9% over 20 minutes and monitor for prophylaxis.

LoE:IIIa

**Note:**

- » In patients with prosthetic heart valves, high dose vitamin K is associated with increased resistance to warfarin and increased risk of thromboembolism. Treat as above, but monitor INR frequently to prevent overcorrection in consultation with a specialist.
- » In all patients on therapeutic warfarin, a major overdose or bleeding episode should prompt careful review of the need for anticoagulation
- » **If warfarin is indicated it should be re-instituted, once the INR is in the therapeutic range.**

**Rodenticide ingestion - Superwarfarins**

Do not given prophylactic vitamin K.

INR >4 or the patient is actively bleeding:

LoE:IVb

- Vitamin K<sub>1</sub> oral, 10–25 mg, daily may be required.
  - Vitamin K<sub>1</sub> is available as a parenteral preparation only, but is safest given orally in anticoagulant poisoning.
  - Treatment with vitamin K<sub>1</sub> may need to be prolonged for several months as superwarfarins are very long acting.
  - Discuss with the Poisons Information Centre or haematologist for advice on dosing and duration of treatment.

Note:

- Administer as a slow IV injection.
- Do not dilute or mix with other injectables.

For patients on long term vitamin K antagonist anticoagulants, e.g. warfarin:

- Temporarily discontinue anticoagulant therapy.
- Decrease Vitamin K dose by half, i.e. Vitamin K<sub>1</sub>, IV, 5 mg. Administer as a slow IV injection.

**No bleeding but INR is raised (INR > 4):**

**Note:** If Vitamin K<sub>1</sub> is only available as a parenteral preparation, administer the same preparation orally as this is safest in anticoagulant poisoning.

Patients NOT on long-term therapeutic anticoagulants and INR > 4.0:

Vitamin K<sub>1</sub>, oral, 10-20 mg.

- Check INR at least 12 hours after vitamin K<sub>1</sub> has been administered. Repeated doses should be guided by further INR (or PT) measurements every 4-6 hours until the patient is stable, and thereafter, every 24 hours. INR (or PT) levels may take 3-4 days to normalise.

Patients on long-term vitamin K antagonist anticoagulant drugs (e.g. warfarin therapy):

If INR 5-8:

- Temporarily discontinue any anticoagulant treatment

Where INR > 8:

Vitamin K<sub>1</sub>, oral, 0.5 – 1.0 mg (one tenth of the normal dose).

- A repeat dose may be given 12-24 hours later if the INR remains ≥ 8.

**Note:**

- These patients are complex and require management in consultation with a haematologist.
- Patients with prosthetic heart valves receiving high-dose vitamin K have a higher risk for increased resistance to warfarin and development of thromboembolism. Treat as above but monitor INR frequently to prevent overcorrection. Treat in consultation with a specialist.
- For patients on other anticoagulant therapies, additional antagonists may be required.
- Warfarin should be re-started once the INR is in the therapeutic range if it is still indicated.
- In patients with superwarfarin toxicity, treatment with vitamin K<sub>1</sub> may need to be prolonged for several months as superwarfarins are very long acting. Discuss with the Poisons Information Centre or haematologist for advice on dosing and duration of treatment.

» Treatment with vitamin K1 may need to be prolonged for several months as superwarfarins are very long acting.

## Superwarfarin poisoning

Vitamin K<sub>1</sub>: *guidance added*

As treatment with vitamin K<sub>1</sub> may be prolonged for superwarfarin poisoning, guidance for consultation with the Poison Information Centre or haematologist was added to the STG text.

### 19.21 HEAVY METAL POISONING

Description: *Editorial amendments*

The description for heavy metal poisoning has been amended to include a flu-like syndrome,<sup>22,23,24</sup> that may present following occupational exposure. Updates to the STG are as tabulated below:

#### DESCRIPTION

This includes mercury, arsenic, gold, copper, lead poisoning, thallium etc.

Frequent/occupational inhalation of metal fumes and particles can cause metal fume fever, a flu-like syndrome with fever, malaise, bronchospasm, and bi-weekly variations in severity that may be mildest on the weekend and most severe on Monday or Tuesday after returning to work. This may be confused with an acute viral illness with fever, cough, sweating, myalgia, headache etc. The course of the illness is usually benign.

## B: CLINICAL EDITORIAL AMENDMENTS

The associated EML chapter has been subject to clinical editorial review following NEMLC ratification of the chapter. These amendments are detailed below.

### 19.2 SNAKE BITES

#### MEDICINE TREATMENT

##### AMENDED FROM:

Antibiotics are seldom needed, except for secondary infection:

##### AMENDED TO:

Antibiotics are seldom indicated unless there is evidence of secondary infection.

### 19.2.1 CYTOTOXIC AND NEUROTOXIC SNAKEBITE

#### NOTE:

##### AMENDED FROM:

» Adverse reactions to antivenom are common and may be severe. Pre-medication with adrenaline (epinephrine) may reduce the risk of severe adverse reactions to polyvalent snake antivenom.

##### AMENDED TO:

Adverse reactions to antivenom such as allergic reactions (10-30%) are common and may be severe. Pre-medication with adrenaline (epinephrine) may reduce the risk of severe adverse reactions to polyvalent snake antivenom.

<sup>22</sup> Brenner BE, Keyes D. Metal Fume Fever. [Updated 2023 Aug 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK583199/>.

<sup>23</sup> Nelson LS, Odujebi OA. Simple Asphyxiants and Pulmonary Irritants. In: Nelson LS, Howland M, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS, eds. Goldfrank's Toxicologic Emergencies, 11e. McGraw-Hill Education; 2019. Accessed April 16, 2024. <https://accesspharmacy.mhmedical.com/content.aspx?bookid=2569&sectionid=210264279>

<sup>24</sup> <https://www.msdmanuals.com/professional/special-subjects/occupational-and-environmental-medicine/metal-fume-fever-and-polymer-fume-fever?query=metal%20fume%20fever%20and%20polymer%20fume%20fever>



## 19.2.2 BOOMSLANG SNAKEBITE

### AMENDED FROM:

#### DESCRIPTION

Boomslang venom is haemotoxic. A consumptive coagulopathy usually sets in within 6–36 hours after the bite with hypofibrinogenaemia and bleeding.

In suspected boomslang bite, a whole blood clotting time is a useful bedside test, especially in rural areas. Place 5 mL of blood in a dry glass test tube and leave at room temperature for 20 minutes. Normal clotting time varies from 5–20 minutes. It is important to repeat these over a few days.

Other investigations include FBC, activated PTT, prothrombin time (INR), fibrinogen, D-dimer and monomers.

### AMENDED TO:

#### DESCRIPTION

Boomslang venom is haemotoxic. A consumptive coagulopathy with hypofibrinogenaemia and bleeding usually sets in within 6–36 hours after the bite.

#### GENERAL MEASURES

- » In suspected boomslang bite, a whole blood clotting time is a useful bedside test, especially in rural areas. Place 5 mL of blood in a dry glass test tube and leave at room temperature for 20 minutes. Normal clotting time varies from 5–20 minutes. It is important to repeat these over a few days.
- » Other investigations include FBC, activated PTT, prothrombin time (INR), fibrinogen, D-dimer, and monomers.

### Boomslang monovalent antivenom

#### AMENDED FROM:

- Re-evaluate regularly, and if after 6 hours there is ongoing evidence of coagulopathy, a repeat dose of 10 mL may be considered.

#### AMENDED TO:

- Re-evaluate regularly: Consider a repeat dose of 10 ml of antivenom if there is ongoing evidence of coagulopathy after 6 hours.

## POISONING

### DESCRIPTION

#### AMENDED FROM:

Suspect intentional ingestion in adults.

#### AMENDED TO:

Maintain a high index of suspicion for intentional ingestion in adults presenting with poisoning.

#### GENERAL MEASURES

#### AMENDED FROM:

It is very important to ascertain if a TOXIC DOSE has been taken BEFORE instituting any potentially harmful decontamination procedures in an asymptomatic patient.

Take a complete and accurate history, ascertain all relevant facts, and do a complete clinical examination. A high index of suspicion is important.

Obtain a collateral history, especially for patients with impaired consciousness. A special effort should be made to obtain tablets, packets, containers, etc. to identify agents involved.

#### AMENDED TO:

It is very important to ascertain if a potentially TOXIC DOSE has been taken BEFORE instituting any potentially harmful decontamination procedures in an asymptomatic patient.

- » Take a complete and accurate history, ascertain all relevant facts, and do a complete clinical examination.
- » Maintain a high index of suspicion.
- » Obtain a collateral history, especially for patients with impaired consciousness. A special effort should be made to obtain tablets, packets, containers, etc. to identify agents involved.

#### Other treatment modalities

##### AMENDED FROM:

Urinary alkalinisation (e.g. severe salicylate or tricyclic antidepressant poisoning)

##### AMENDED TO:

Sodium bicarbonate alkalinisation

Urine alkalinisation enhances renal elimination of certain toxins (salicylates) and serum alkalinisation improves acidosis enhancing myocardial functioning (TCAs) and reducing neurotoxicity (salicylates).

This is achieved by administering intravenous sodium bicarbonate (NaHCO<sub>3</sub>) to maintain a urinary pH 7.5-8.5 or serum pH 7.45-7.55.

#### Once medically stable:

##### AMENDED FROM:

Assess and manage a substance use disorder

- » quantify the amount of substance used and related harms, e.g. with ASSIST ([http://www.who.int/substance\\_abuse/activities/assist/en/](http://www.who.int/substance_abuse/activities/assist/en/)) or DUDIT (<https://paihdelinkki.fi/sites/default/files/duditmanual.pdf>) rating scales and discuss with patient.
- » provide brief intervention with motivational interview.
- » refer for rehabilitation.

##### AMENDED TO:

Assess and manage a substance use disorder:

- » Quantify the amount of substance used and related harms with these rating scales and discuss findings with the patient:
  - ASSIST: [http://www.who.int/substance\\_abuse/activities/assist/en/](http://www.who.int/substance_abuse/activities/assist/en/)
  - DUDIT: - <https://www.emcdda.europa.eu/system/files/attachments/12173/DUDIT-English-version.pdf>
- » Provide brief intervention with motivational interview.
- » Refer for rehabilitation.

### 19.5.1 PARACETAMOL POISONING

#### Acute single ingestion <8 hours post-ingestion:

##### AMENDED FROM:

- » Perform a serum paracetamol level 4 hours post-ingestion and ALT.
- » If serum paracetamol level results will not be available before 8 hours post-ingestion, and the patient has taken a toxic dose, do not delay initiation of NAC. It can always be stopped if the serum level plotted on the nomogram does not indicate its continued use.

##### AMENDED TO:

- » Perform a serum paracetamol level and ALT no earlier than 4 hours post-ingestion.
- » If serum paracetamol level results will not be available before 8 hours post-ingestion, AND the patient has taken a toxic dose, do not delay initiation of NAC. It can always be stopped if the serum level plotted on the nomogram does not indicate its continued use.

#### MEDICINE TREATMENT

##### AMENDED FROM:

Histamine may be released, which mimics an allergic reaction. If this occurs and the patient is stable, infusion may continue at a slower rate under antihistamine cover. In the presence of bronchospasm, stop the infusion.

##### AMENDED TO:

Histamine may be released, which mimics an allergic reaction. If this occurs and the patient is stable, infusion may continue at a slower rate under antihistamine cover. Stop the infusion if bronchospasm occurs.

### 19.5.3 OPIOID POISONING

#### GENERAL MEASURES

##### AMENDED FROM:

Body packers/stuffers:

Patients may ingest packages of heroin, and are at great risk of life-threatening toxicity in the event of rupture.

##### AMENDED TO:

Body packers/stuffers:

Patients may ingest packages of illicit opioids and are at increased risk of life-threatening toxicity in the event of rupture.

#### MEDICINE TREATMENT

##### AMENDED FROM:

- Naloxone, IV, 0.4 mg immediately, in patients with significant respiratory depression.
  - Effectiveness is limited by a half-life ( $\pm$  1 hour) that is shorter than most opioids; therefore repeated incremental doses (e.g.: 0.4 mg, 0.8 mg, 2 mg, 4 mg etc.) may be needed at 2 to 3 minute intervals, followed by a naloxone infusion of 0.4 mg/hour.
  - If there is no response after a maximum total dose of 10 mg of naloxone is administered, the diagnosis of opioid-induced or partial opioid-induced toxicity should be questioned.

Consider intramuscular or subcutaneous administration if the intravenous route is not available

##### AMENDED TO:

Naloxone, IV, 0.4 mg immediately, in patients with significant respiratory depression.

- Effectiveness is limited by a half-life ( $\pm$  1 hour) that is shorter than most opioids.
- Repeated incremental doses (e.g.: 0.4 mg, 0.8 mg, 2 mg, 4 mg etc.) may be required at 2 to 3 minute intervals, up to a maximum of 10 mg. If a response is noted, a maintenance infusion of 0.4 mg/hour should be initiated.
- If there is no response after a maximum total dose of 10 mg of naloxone is administered, the diagnosis of opioid-induced or partial opioid-induced toxicity should be re-assessed.

Consider intramuscular or subcutaneous administration if the intravenous route is not available

### 19.6.1 TRICYCLIC ANTIDEPRESSANT POISONING

#### GENERAL MEASURES

##### AMENDED FROM:

- » Discharge patients only when
  - asymptomatic, or
  - mild symptoms/signs of toxicity and ECG has normalised for 24 hours.

##### AMENDED TO:

Discharge patients only when:

- asymptomatic, or
- mild symptoms/signs of toxicity and ECG has normalised for at least 24 hours.

## MEDICINE TREATMENT

### AMENDED FROM:

Serum alkalinisation for all patients with:

- » ventricular dysrhythmias,
  - » prolonged QRS >100 msec
  - » hypotension unresponsive to fluids or
  - » seizures.
- Sodium bicarbonate, IV 1–2 mEq/kg as an 8.4% solution, as bolus doses to achieve a pH of 7.45–7.55 (Specialist consultation).
    - Monitor acid-base status, serum potassium and sodium.
    - If sodium bicarbonate is unavailable or fluid restrictions limit intake, consider hyperventilation of intubated patients.

### AMENDED TO:

Indications for serum alkalinisation:

- » ventricular dysrhythmias,
  - » prolonged QRS >100 msec,
  - » hypotension unresponsive to fluids, or
  - » seizures.
- Sodium bicarbonate 8.4% solution, IV 1–2 mL/kg administered in bolus doses (Specialist consultation).
    - Aim to achieve a serum pH of 7.45–7.55.
    - Monitor acid-base status, serum potassium and sodium.
    - If sodium bicarbonate is unavailable or fluid restrictions limit intake, consider hyperventilation of intubated patients.

## 19.9.1 BENZODIAZEPINE POISONING

### AMENDED FROM:

#### DESCRIPTION

Patients present with depressed levels of consciousness, confusion, ataxia and dysarthria. Benzodiazepines are unlikely to cause significant respiratory depression unless co-ingested with alcohol or other CNS depressants. However, in the elderly, the danger of respiratory depression with overdose exists. Management is supportive and ventilation may be required

### AMENDED TO:

#### DESCRIPTION

Patients present with depressed levels of consciousness, confusion, ataxia, and dysarthria. Benzodiazepines are unlikely to cause significant respiratory depression unless co-ingested with alcohol or other CNS depressants. However, there is a risk of respiratory depression due to overdose in the elderly.

#### GENERAL MEASURES

Management is supportive, and ventilation may be required.

## 19.9.2 LITHIUM POISONING

## MEDICINE TREATMENT

### AMENDED FROM:

Correct electrolyte abnormalities: see section: 7.2 Major electrolyte abnormalities.

For seizures: R56.8 + (T43.9/X44.99/X69.99/Y14.99)

Treat with benzodiazepines - see section: 14.4.1 Status epilepticus.

**Note:** Phenytoin should be avoided (due to potential cardiotoxicity)

### AMENDED TO:

If ingested dose is potentially toxic or modified-release products were ingested, consider WBI.

- » Hydration: administer sodium chloride, 0.9 % to maintain urine flow of 1–2 mL/kg/hour while preventing hypernatremia.
- » Correct electrolyte abnormalities: see section: 7.2 Major electrolyte abnormalities.
- » For seizures: Treat with benzodiazepines – see section: 14.4.1 Status epilepticus.  
Note: Phenytoin should be avoided (due to potential cardiotoxicity).

## 19.10 ISONIAZID POISONING

### DESCRIPTION

#### AMENDED FROM:

Acute toxicity can present with the classic triad of seizures, metabolic acidosis and coma. Seizures are generalised tonic-clonic and often refractory to standard anticonvulsant therapy.

#### AMENDED TO:

Acute toxicity can present with the classic triad of seizures, metabolic acidosis, and coma. Seizures are of a generalised tonic-clonic type, and often refractory to standard anticonvulsant therapy.

## 19.14.1 COCAINE POISONING

### Body packers/stuffers:

#### AMENDED FROM:

Body packers/stuffers:

- » Patients may ingest packages of cocaine, and are at great risk of life-threatening toxicity in the event of rupture.
- » Abdominal X-rays or CT scan may show packages.

#### AMENDED TO:

Body packers/stuffers:

- Patients may ingest packages of cocaine and are at increased risk of life-threatening toxicity in the event of rupture.
- Abdominal X-rays or CT scan may be helpful in identifying packages.

## 19.16 INGESTION OF CAUSTIC SUBSTANCES

### DESCRIPTION

#### AMENDED FROM:

Depending on the concentration, caustic substances can cause necrosis of the gut mucosa and underlying tissue resulting in acute perforation especially with strong alkalis and possible strictures later with both acids and alkalis.

#### AMENDED TO:

Caustic substances can cause necrosis of the gut mucosa and underlying tissue, resulting in acute perforation (particularly strong alkalis), and possible strictures later (which can occur with acids and alkalis). Concentrated caustic substances are more corrosive and present a higher risk for necrosis.

## 19.17.3 METHANOL POISONING

### DESCRIPTION

#### AMENDED FROM:

No longer found in methylated spirits as methanol replaced with less toxic agents 10-20 years ago. Methanol may be found in stove or model fuels, or in antifreeze and windscreen washes.

#### AMENDED TO:

Methanol, once present in methylated spirits, was replaced with less toxic agents 10-20 years ago. However, it may still be found in stove or model fuels, as well as in antifreeze and windscreen washes.

## 19.18.2 ORGANOPHOSPHATE POISONING

### DESCRIPTION

#### AMENDED FROM:

Absorption occurs through the skin, when the agent is taken orally, or by inhalation

#### AMENDED TO:

Absorption may occur through the skin, gastrointestinal tract if taken orally, or by inhalation.